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Autosomal Recessive Cerebellar Ataxia (ARCA) develops as a result of inefficient protein 
turnover and further accumulation of damaged proteins inside the cells. Some of mutations 
associated with ARCA are identified in the STUB1 gene which encodes CHIP (C-terminus of 
Heat shock protein 70-Interacting Protein) as a dimeric co-chaperone and E3 ubiquitin ligase 
protein. Currently, there is limited information available regarding the role of these mutations in 
the pathogenesis of ARCA. This study aims to characterize the effects of six selected mutations 
on the structure and function of CHIP, mainly by the use of in vitro methods.  
Mutant CHIP constructs were created by site-directed mutagenesis, and recombinant proteins 
were subjected to different assays including ubiquitination activity assay, limited proteolysis, 
oligomerization analysis, and circular dichroism spectroscopy. Results indicated that mutations 
N65S and T246M were associated with more severe consequences compared to the rest (E28K, 
K145Q, M211I, and S236T). Impaired Hsc70-ubiquitination activity was observed for both N65S 
and T246M. The N65S mutation resulted in more stabilized and compact protein structure, while 
the T246M mutant presented more flexible and loose structures with a high tendency for 
aggregation. The other mutations investigated were associated with intact ubiquitination activity, 
but showed lower protein stability and loss of some secondary structures, although to a lesser 
extent when compared to T246M.  
Altogether, this study provides insights into the development of ARCA through demonstrating 
the effect of STUB1 mutations in the expression of damaged CHIP proteins unable to participate 
efficiently in the protein turnover system, which may lead to toxic accumulation of abnormal 






1.1 Protein quality-control system 
Being the chief actors within the cells, proteins are involved in nearly every concept of cellular 
life including shape, structure, biochemical pathways, movement, communication, and signaling. 
Protein functionality requires achieving a stable, defined native structure as well as maintaining 
conformational flexibility. Therefore, all the proteins must be folded correctly after being 
produced by the ribosomes. However, the optimal folded state of the proteome is constantly 
under the effect of changes in the environment such as heat, oxidation, and ultraviolet stress, 
causing subjection to various types of protein misfolding [1]. In addition to this, the high density 
of protein molecules inside the cytosol can increase the likelihood of protein denaturation and 
aggregation [2]. For this reason, a protein quality control system has been designed inside the 
cells to ensure that all the proteins are folded properly and to get rid of abnormal proteins. 
Marques et al. introduced a model called the “Triage Model” to describe this system in 2006 [3].  
 
Figure 1.1.1 Triage model of protein quality control system. The intrinsic signals (red) for interaction 
with molecular chaperones or the components of ubiquitination system are normally hidden inside the 
protein native structure. Under stressful conditions, such as heat or oxidation, these signals are exposed as 
a result of protein unfolding. These areas are then recognized by Hsp70 or Hsp90 molecular chaperones 
which function in collaboration with co-chaperones to refold the protein structure. If the protein cannot be 
refolded in this way, it will be instead targeted for ubiquitination and proteosomal degradation. However, 
the ubiquitinated protein might still have a second chance of refolding with deubiquitination activity of 
isopeptidases. Thus, the efficiency of protein quality control system relies on the competitive relationship 
existing between the molecular chaperones and the ubiquitin-proteasome pathway (UPP). Ub, Ubiquitin.  





According to this model, a protein turnover system functions through the interaction between 
molecular chaperones and the ubiquitin-proteasome pathway (UPP). Most of the proteins are 
predicted to have intrinsic signals such as hydrophobic patches hidden in their native 
conformation which can interact with molecular chaperones and ubiquitin-proteasome system 
compartments. Once the protein is denatured, these recognition signals will be exposed to 
molecular chaperones such as Hsp90 or Hsp70 and the protein will be refolded in an ATP-
dependent manner. Those proteins which are not able to be refolded rapidly in this pathway will 
be ubiquitinated and degraded by the 26S proteasome, unless they can be alternatively 
deubiquitinated by isopeptidases once again and have a second chance of being refolded by 
molecular chaperones. Therefore, there is a competitive functional relationship between the UPP 
and molecular chaperones which determines the fate of a damaged protein inside the cell (Figure 
1.1.1) [3-5]. 
 
1.2 Molecular chaperones help to fold/refold the proteins 
The initial folding of proteins necessitates participation of molecular chaperones to help them 
achieve a stable conformation. Some proteins do not interact with chaperones due to the high 
stability of their structure. Yet, about 10-20% of newly synthesized proteins are found associated 
with chaperones once they are out of the ribosome “exit site” [6, 7]. In addition, many proteins 
may suffer damage as a result of environmental stress including oxidative mechanisms and heat 
shock, as well as different mutations in their encoding genes. These proteins are recognized and 
refolded by molecular chaperones in the first level of the protein quality control system. This 
implies the crucial role of chaperones against protein misfolding and aggregation. There are 
several highly conserved families of the so-called “Heat shock proteins (Hsp)” involved in 
protein folding and remodeling. These proteins work as ATP-dependent chaperones together with 
several regulatory co-factors (co-chaperones). The two most well-studied families of the heat 
shock proteins are Hsp (Hsc)70 and Hsp90.  
The family of Hsp70 chaperones represents the central component of the protein quality control 
system, assisting a large variety of protein de novo folding processes in the cell. It has been 
shown that ATP cycles of binding and hydrolysis are essential for the activity of these 
chaperones. In the ATP-bound state, Hsp70 makes short-term interactions with the peptide 





substrate within the amino terminal Polypeptide Binding Domain (PBD) of the chaperone, 
resulting in longer association of the substrate within the PBD. This allosteric regulation of 
Hsp70 binding affinity is controlled by specific co-chaperones and nucleotide exchange factors 
[8]. 
There are several Hsp70 isoforms present in the cell having significant degrees of sequence 
conservation and overlapped functions. They are mainly detected in the cytosol, but can also 
perform essential functions in endoplasmic reticulum and mitochondria. In spite of similarities in 
their structure and enzymatic activity, these isoforms differ remarkably in the way their 
expression is regulated in each hosting tissue and during different developmental stages. Genome 
sequencing studies confirmed the presence of 17 genes and 30 pseudogenes with a high number 
of mRNA variants that encode Hsp70 isoforms both as organelle-specific and cytosolic 
chaperones. According to these studies, the organelle-specific Hsp70s are generally encoded by a 
single gene while those isoforms existing in the same cytosol are very often encoded by different 
homologous genes. These cytosolic Hsp70s consist of six canonical members including Hsp70-
1a, Hsp70-1b, Hsp70-1t, Hsp70-2, Hsp70-6 and Hsc70.  Some isoforms, including Hsc70 are 
constitutively expressed and play important housekeeping functions in the cell. However, the 
expression of other isoforms such as Hsp70-1a, Hsp70-1b and Hsp70-6 is induced under stress 
conditions. For each type of harsh condition, there are only specific isoforms capable of efficient 
binding to the protein substrates and/or co-chaperons and surviving in the cell, which explains the 
need of the cell for multiple Hsp70 isoforms in a complex organism [9-13]. 
While the Hsp70 chaperones help with the initial folding of the newly synthesized polypeptides, 
the Hsp90 family is involved mostly in the final maturation of proteins. For this, the chaperone 
needs to recognize certain conformations in the client protein rather than the primary sequence. 
Like Hsp70, the activity of an Hsp90 chaperone is regulated by ATP cycles; once the ATP is 
bound, the chaperone achieves a “tense” conformational state functioning as a clamp to hold the 
substrate.  Upon ATP hydrolysis and in the “relaxed” state, the clamp is open and the substrate is 
released [14, 15]. 
Hsp90 is found to be involved in the UPP and protein degradation as well [5]. This finding was 
further supported by the discovery of CHIP (Carboxyl terminus of Hsp70-Interacting Protein) as 





Hsp90 and participate in their functions. These co-chaperones can act by presenting a client 
protein to the chaperones as well as regulating the ATP cycles of binding and release of the 
chaperone in favor of protein folding or disassembly. To interact with chaperones, most of the co-
chaperones adopt one of the two main classes of domains: the “J” domain found in Hsp70 co-
chaperones like Hsp40, and the Tetratrico Peptide Repeat (TPR) domain found in co-chaperones 
interacting with Hsp70 or Hsp90 such as HIP, HOP and CHIP. TPR domain co-chaperones can 
take part in various biological processes due to the additional domains in their structure that 
catalyze different reactions such as ubiquitin ligation which is observed in CHIP [16, 17]. These 
co-chaperones are explained in more detail in Section 1.4. 
 
1.3 Ubiquitin-proteasome pathway mediates protein degradation 
As an ultimate mechanism to ensure quality control of proteins, the cell degradative machinery is 
designed to target damaged proteins for destruction after being labeled by ubiquitin in an 
enzymatic conjugating cascade. This process can be part of the protein turnover system wherein 
aged proteins are continually being degraded and replaced by new ones, or it can selectively 
destruct those abnormal proteins that have resulted from different types of mutations and folding 
errors. There is a high tendency for misfolded proteins to accumulate and form toxic aggregates. 
Aggregation happens through association of exposed hydrophobic domains that are normally 
buried inside the protein structure. In fact, intracellular aggregates are formed when the 
production of misfolded proteins exceeds the cell capacity for protein degradation. This situation 
can be found in various inherited neurodegenerative diseases in which inclusions lead to cell 
death (for more information on protein aggregation diseases, see Section 1.6). Therefore, 
studying the cellular proteolytic pathways is crucial for understanding the pathogenesis of such 
diseases as well as developing new therapies [18]. 
1.3.1 Ubiquitination pathway 
Ubiquitin is a 76-residue polypeptide which covalently binds to the intracellular proteins in the 
process called ubiquitination (ubiquitylation) and targets them to different fates. During 
ubiquitination, the C terminus of ubiquitin (G76) binds to the Ɛ-amino group of a substrate lysine 
residue by means of the sequential actions of three enzymes: an activating enzyme (E1) uses ATP 





ubiquitin is then transiently carried by a conjugating enzyme named Ubc13 (E2) and finally 
delivered to a ligase (E3) that transfers the ubiquitin to the lysine residue of the substrate it is 
bound to. In such a manner, the ubiquitins are added progressively to the substrate until the 
multiubiquitin chain becomes long enough to be recognized by the proteasome for degradation 
(Figure 1.3.1.1) [19]. 
Studying the ubiquitin fusion degradation (UFD) pathway of ß-galactosidase in yeast, Koegl et 
al. discovered a new type of ubiquitination enzymes, called E4, which is required for the 
assembly of the polyubiquitin chain on the substrate along with the E1, E2, and E3 enzymes [20]. 
Further studies identified E4’s affinity only for those substrates that are modified by ubiquitin. 
Therefore, the E4 activity was proposed to be a specialized type of E3 enzyme activity in which 
the oligoubiquitinated artificial fusion proteins serve as substrates [21]. Today, E4 enzymes are 
known to be required for efficient multiubiquitination and proteosomal targeting of the substrates 
through affecting the linkage between individual ubiquitin molecules in cells being exposed to 
stress conditions [22]. 
 
Figure 1.3.1.1 The ubiquitination pathway and its associated enzymes. The E1 enzyme binds to 
ubiquitin in an ATP-dependent manner (1). The activated ubiquitin is then carried by E2 enzyme and 
delivered to the E3-substrate complex (2). The E3 ligase transfers ubiquitin to the protein substrate either 
directly or indirectly (3). This process continues repeatedly until the resulted ubiquitin chain is long 
enough to be recognized by the 26S proteasome machinery and the protein is degraded (4). Meantime, 
ubiquitins are released by deubiquitination enzymes (DUBs) for further re-use (5). Pi, inorganic 
phosphate, ppi, pyrophosphate; Ub, ubiquitin. The figure is adapted from [23]. 
Studies focusing on the molecular structure of E3 ligase have identified three families of E3 
enzymes. These families act differently while transferring ubiquitin to the substrate: (a) a large 
family of E3 ligases that share the HECT (Homologous to the E6-AP Carboxyl Terminus) 





cysteine residue which binds to ubiquitin and forms a thiol ester intermediate, therefore these 
ligases catalyze ubiquitination of the substrate directly. (b) Other E3s share the RING (Really 
Interesting New Gene) finger domain which is a ~70-residue region with a globular conformation 
resulting from the two zinc ions in its structure. Enzymes with RING finger domain do not 
interact with ubiquitin themselves. Instead, they facilitate ubiquitination by bringing the target 
protein close to the E2 enzyme. (c) The last family of E3s shares a modified form of RING 
domain, termed U-box domain, which functions like the RING domain yet lacks the hallmark 
metal-chelating residue in its structure. The U-box domain has a conformation similar to that of a 
RING finger in which the stabilization is achieved by intermolecular forces (electrostatic 
interactions) rather than metal ion coordination (Figure 1.3.1.2) [19, 21].  
                      
Figure 1.3.1.2 Three classes of E3 ubiquitin ligases act differently while transferring ubiquitin to the 
protein substrate. E3 enzymes sharing the HECT domain (left) bind to ubiquitin and participate in the 
delivery process via forming a thiol-ester intermediate. However, the RING finger and U-box domain-
containing enzymes (right) do not interact with ubiquitin directly. Instead, they serve as a scaffold, 
bringing E2 and the protein substrate close together for interaction. These domains differ structurally in 
the presence of Zn
2+
 coordinating sites which are replaced with stabilizing hydrogen bonds and salt 
bridges in the U-box domain. Ub, Ubiquitin. 
A ubiquitin-labeled protein is destined to different fates based on its subcellular localization, and 
the number and topology of the conjugated ubiquitins. For example, polyubiquitin chains 
conjugated by K48-G76 isopeptide bonds often target the substrate to the proteasome, opposite to 
those linked through K63-G76 bonds that are involved in non-proteolytic signaling. In further 
contrast, the substrates marked by one or a few ubiquitins are subjected to endocytosis and 





1.3.2 The 26S proteasome 
The 26S proteasome is a 2500 kDa multiprotein complex with ~31 different subunits designed 
for protein degradation in eukaryotic cells. Studies using proteasome inhibitors have reported a 
huge number of cellular proteins (80-90%) to be degraded by the proteasome. These proteins are 
first recognized by their covalently attached ubiquitin labels in the 19S regulatory complexes 
located at both ending sites of the proteasome. Thereby, small conformational changes caused by 
the binding of a polyubiquitinated substrate will be used for its unfolding and translocation into 
the core complex known as the 20S proteasome. Proteolytic degradation happens once the 
ubiquitin molecules are released and the protein passes through the barrel-shaped 20S particle. 
Finally, small oligopeptides emerge from the proteasome and these are broken down into single, 
free amino acids by a number of ATP-dependent proteases [24]. 
From a structural point of view, the 20S proteasome of eukaryotes consists of 28 α- and ß- type 
subunits composing four stacked rings surrounding a central cavity. The two innermost ß-rings 
form the central proteolytic chambers with proteolytic sites: two sites that cleave after 
hydrophobic residues, two after acidic residues and two after basic residues; thus cutting most 
types of peptide bond. Substrates can enter the 20S complex passing through the narrow channel 
enclosed by the two outer α-rings. Before entering the channel, proteins need to be fully 
linearized in an ATP-dependent mechanism provided by the 19S proteasome. For this purpose 
there are 6 ATPase rings located in the base part of the 19S regulatory complex. The lid complex 
forms a distal mass on the outermost parts of the proteasome and contains 8 subunits necessary 
for degradation of the ubiquitinated, target protein [25].  
 
1.4 CHIP: a link between the chaperone and proteasome system 
As a co-chaperone with “anti-chaperone” functions, CHIP can interact with Hsp70 and Hsp90 
and inhibit their folding activity through interfering with the ATPase cycles of Hsp70 or 
prevention of Hsp90’s interaction with other co-chaperones [26, 27]. CHIP was identified as a 
TPR domain-containing protein during a human cDNA library screening carried out in 1998 
looking for all the proteins with a TPR domain that might be involved in stress regulation. 
Interestingly, structural analysis showed similarities between the C-terminus of this protein (the 
U-box) and the E3 ligase component of the ubiquitination proteasome pathway, suggesting an 





discovered as the first ubiquitin ligase that directly associates with molecular chaperones [26-28]. 
As mentioned earlier, those non-native proteins unable to be refolded by chaperones are directed 
to the proteasome for degradation. This action is mediated by the interaction of CHIP with the 
chaperone-substrate complex through which the substrate is prevented from release and labeled 
for degradation by the ubiquitin ligase activity of CHIP. Although the ubiquitination activity of 
CHIP via its U-box domain has been confirmed by several studies, the mechanism by which the 
non-native protein clients are selected for this process is not fully understood. Some studies 
suggest the presence of an intrinsic polypeptide binding activity that enables CHIP to recognize 
and selectively bind non-native protein structures in both chaperone-dependent and –independent 
manners. However, the mechanistic details of how such a selective interaction between CHIP and 
Hsp70 influences substrate binding and release cycles require further investigation [29].   
                
Figure 1.4.1. The ubiquitination activity of CHIP. CHIP mediates ubiquitination of misfolded proteins 
via its U-box domain which binds to E2 ubiquitin ligase and facilitates ubiquitin transfer to the substrate. 
The TPR domain is used to interact with Hsp70, bridging CHIP to the targeted misfolded protein. CHIP 
and the Hsp70 molecular chaperone are subjected to ubiquitination as well. Several hypotheses have 
been put forward to explain this phenomenon. Ub, ubiquitin. Figure adapted from [30]. 
                                                  
The ubiquitination activity of CHIP is not limited to the protein substrate. The molecular 
chaperone to which the substrate is bound and the CHIP itself seem to be subjected to 
ubiquitination as well (Figure 1.4.1). Different theories have been proposed to explain this 
phenomenon. It can be considered as an auto-regulation strategy by which the ubiquitinated 
Hsp70/CHIP molecules are targeted to the proteasome during stress recovery when the non-





Hsp70 can be studied regarding the fact that the ubiquitin chains observed on the Hsp70 
molecules are both short and atypical (other than Lys 48 linked), suggesting that these chains can 
act as a targeting sequence during the signaling events rather than recognition signals for the 
proteasome. In this way, by ubiquitination of Hsp70, CHIP directs the chaperone towards a 
particular signaling pathway such as the endosome-to-lysosome trafficking [32, 33]. In other 
studies, CHIP self-ubiquitination is suggested to regulate its ligase activity and the substrate 
recruitment [34]. 
In addition to CHIP, the Hsp70 co-factor BAG-1 is also known to regulate chaperone’s functions 
negatively by acting as a link between the molecular chaperones and ubiquitin/proteasome 
system.  Once BAG-1 binds to the Hsp70-protein complex, its N-terminal ubiquitin-like domain 
is recognized by the proteasome components at the same time, ending up in the facilitated 
transfer of the complex to the proteasome. Besides, the ubiquitinated substrates are promoted to 
become separated from Hsp70 in the presence of BAG-1. Therefore, BAG-1 acts in concert with 
CHIP to target the non-native chaperone substrates for ubiquitination-mediated degradation [26, 
27, 35]. On the other hand, several co-chaperones including HIP, HOP, and Hsp40 assist the 
folding activity of Hsp70 and Hsp90 in different ways. While HIP and Hsp40 increase Hsp70’s 
affinity for substrates by binding to its ATPase domain and stabilizing the ADP-bound 
conformation, HOP promotes cooperation between Hsp70 and Hsp90 in a way that the substrate 
is efficiently transferred between them [17]. Maintenance of cellular homeostasis requires a 
balance between protein folding and degradation pathways. This balance is controlled by the 
folding kinetics of the protein substrates and the activity network of different co-chaperones that 
enable them to associate with the molecular chaperones and assist them in either folding or 
degrading the substrate. The two co-factors CHIP and HOP appear to compete on a common TPR 
acceptor site on Hsp70 and Hsp90. Similarly, HIP and BAG-1 bind to the molecular chaperones 
via their C-terminal competitively. Under normal conditions, the lower intracellular 
concentrations of CHIP and BAG-1, in comparison to the folding-inducing co-chaperones, direct 
the cell condition in favor of protein folding, whereas the over-expression of CHIP during stress 





1.5 CHIP: structures and interactions 
CHIP is an evolutionary conserved ~35 kDa protein which is highly expressed as a dimeric co-
chaperone in tissues that are active in terms of metabolism and protein turnover, such as brain, 
heart, and skeletal muscle. The significant amino acid sequence similarity existing between 
human and mouse CHIP (98%), makes the latter animal a powerful model for in-depth 
characterization of the structural properties of CHIP and its interacting partners [35]. There are 
two main domains involved in the primary structure of CHIP: a C-terminal U-box domain which 
facilitates ubiquitination of the chaperone substrates through the interaction with different E2 
enzymes, and an N-terminal TPR domain which mediates the interaction of CHIP with Hsp70 
and Hsp90 molecular chaperones. These domains are separated by a central Helical Hairpin (HH) 
region (also termed the central Coiled-Coil (CC) domain) which itself plays an important role in 
the dimerization and stability of the whole protein [36].  In order to become dimerized, the U-box 
domain and the distal segment of the helical hairpin of the two separated CHIP monomers 
interact symmetrically through their strongly conserved amino acid chains, providing the two 
cores of the dimer interface (Figure 1.5.1  A) [37].  
Three pairs of TPR motifs together with an elongated seventh helix form a super helical domain 
with distinct ligand binding grooves at the N-terminal of the CHIP protein. Each TPR motif is 
~34 residues in length and consists of two antiparallel α-helices connected by a short turn. At the 
end of the TPR domain, where it meets the central dimerization region, there is an extended α-
helix packing against the third TPR motif with two different positions. This causes the TPR 
domain to adopt different conformations in each protomer of the homodimeric CHIP (Figure 
1.5.1 B). Two characteristic carboxylate clamps are found within the grooves of the TPR domain 
to interact with the C-terminal EEVD motifs of Hsp70 and Hsp90 selectively. Different amino 
acid residues located upstream of the EEVD motifs in Hsp70 and Hsp90 chaperones explain the 
specificity of their interaction with CHIP (Figure 1.5.1 C) [38-40]. 
At the C-terminal, CHIP is composed of a pair of ß-hairpins continued by two α-helices with 
another hairpin in between.  In contrast to the TPR domain, the structure of the U-box domain is 
similar in both protomers. As an E3 ligase, each U-box domain of CHIP interacts with Ubc13 
(E2) through the association of hydrophobic grooves on the U-box surface and the conserved Ser- 





mouse CHIP have reported an asymmetry in this interaction via the detection of only one 
ubiquitin conjugating system coupled to a dimeric CHIP. In fact, as a consequence of having 
different conformations, the TPR domain interacts with its associated U-box and prevents the 
binding of E2 in one protomer of the CHIP dimer, while there is no obstacle for the interaction 
with E2 in the opposing protomer. Therefore, CHIP displays a “half-of-sites” activity in the 










 C.    
         
Figure 1.5.1  Architecture of the CHIP protein homodimer. A) CHIP protein domain and secondary 
structure cartoon of the homodimer from the N (orange) to C (green) terminus: The TPR and U-box 
domains are linked through the central coiled-coil (CC) region (blue). B) Asymmetric disposition of TPR 
domains: The two TPR domains of a dimeric CHIP are located asymmetricaly due to different structure of 
the extended helix 7 (blue) in the two protomers. In one (right), the α-helix is formed straight from Asp 
134 to Arg 155. In the other (left), the polypeptide is broken in two separate α-helices: Asp134-Arg155 
and Glu161-Arg183. C) detailed view of the Hsp90 C-terminal bound to the CHIP TPR domain: The C-
terminal EEVD sequence lies along the TPR channel in both Hsp70 and Hsp90 molecular chaperones. 
Yet, different amino acids located at the upstream side chains interact with TPR domain specifically. All 





1.6 Protein aggregation and neurodegenerative diseases 
Mutations leading to “loss of function” of a single protein are the most probable cause of 
recessively inherited monogenic diseases [42]. Such mutations can either reduce the activity level 
or the steady-state concentration of the protein inside the cell. There is evidence suggesting that 
missense mutations can accelerate the degradation of a protein in two possible ways. First, they 
can decrease the thermodynamic stability of the protein through enhancing the level of free-
energy inside the native conformation and therefore increase its potency for unfolding. Second, 
these mutations can decrease the rate of correct folding of a protein via affecting its kinetic 
partitioning in a way that smaller amounts of protein enter the correct folding pathway once they 
are synthesized as polypeptide chains [42, 43]. The misfolded or damaged proteins are normally 
removed in cells via the protein degradation system. However, in some cases, when the load of 
unfolded proteins overreaches the amount of available chaperones and cell capacity for protein 
degradation, these proteins start to accumulate and form toxic aggregates inside the cell. This 
notion is supported by the observation of chaperones and components of ubiquitin proteasome 
pathway inside the aggregations. The accumulation of abnormal, damaged proteins appear as a 
type of disorders with gain of (abnormal) function phenotype, named “aggregation disorders” 
[42]. A large number of dominantly inherited disorders and many neurodegenerative diseases can 
develop in this way. The presence of protein aggregates as intra-neuronal inclusions is a common 
morphological feature and the hallmark of all neurodegenerative diseases. These lesions were 
first detected in neurofibrillary tangles and further recognized in the cytoplasm of neurons in 
patients hosting diseases such as Alzheimer’s, Parkinson, and Huntington [44].  
Further studies in this area have provided insight into the pathophysiological importance of 
aggregated proteins: once the protein is unfolded, exposed hydrophobic structures on its surface 
interact with each other in order to minimize the contact area to the hydrophilic environment. 
This, together with other non-covalent and cross-linking interactions, form a protein aggregate 
which increases in size by addition of more proteins to the surface over time. The resulting 
aggregates trigger a set of intracellular reactions ending up in toxicity and cell death [45]. 
Surprisingly, there has been an increasing number of studies over the past few years reporting 
little correlation between the level of protein aggregation and toxicity in cells associated with 





misfolded protein intermediates which are produced on the pathway to inclusions and can be 
detected by proteasomes for degradation. Yet, due to the high amounts of ß-sheets in their 
structure, their full entry to the proteasome is resisted, resulting in steric occlusion of the 
proteasome. In this way, protein aggregation is considered as a new mechanism of protein quality 
control system through which unfolded proteins are directed to specific cellular compartments for 
subsequent removal [46-48].  
Different factors are known to be responsible for abnormal protein folding, such as mutations, 
defects in protein biogenesis, environmental stresses including the presence of reactive oxygen 
species (ROS) inside the cell, and aging, which is characterized by reduced capacity of the 
protein quality control system for eliminating misfolded proteins. There are two sets of mutations 
resulting in protein unfolding and subsequent aggregation. Some mutations are believed to 
modify protein structure, and increase its tendency towards misfolding. Expanded CAG 
trinucleotide repeats in Huntington disease (HD), and mutations responsible for the development 
of various conformational diseases such as type 2 diabetes are examples of this type. Other 
mutations are found in genes encoding components of the protein quality control system. For 
instance, mutations in PARKIN (encoding an E3 ligase) are known to be strongly associated with 
Parkinson disease (PD) [48]. CHIP, as another E3 ligase enzyme in the protein ubiquitination 
pathway is subjected to various mutations in the Cerebellar Ataxia Diseases [49]. Cerebellar 
Ataxias (CA) consist of a wide range of inherited and sporadic neurodegenerative disorders in 
which ataxia, or the loss of coordination, is considered as the main phenotype. A general 
classification of the common ataxia subtypes is given in Figure 1.6.1.  
Patients with CA may suffer from balance and gait impairments as well as speech, vision, and 
cognitive disabilities [49, 50].  Repeat expansions in either coding or non-coding parts of the 
genome are responsible for the majority of inherited ataxias. For example, a gene called FXN 
contains a tri-nucleotide sequence (GAA) that is normally repeated between 7 and 22 times. 
However, when defective, the repeat can expand to hundreds. Alleles containing GAA 
expansions of 90-1700 repeats are associated with the development of Friedreich Ataxia (FA) - 
the most common type of Autosomal Recessive Cerebellar Ataxia (ARCA) [51]. Other rare 






Figure 1.6.1 General classification of Cerebellar Ataxia diseases. MSA, multiple system atrophy/ 
OMIM #146500; ILOCA, idiopathic late-onset cerebellar ataxia; DRPLA, dentatorubral pallidoluysian 
atrophy/ OMIM #125370; SCA, spinocerebellar ataxia/ OMIM #164400; HD, Huntington disease/ 
OMIM #143100; HDL, Huntington disease-like/ OMIM #603218; FA, Friedreich ataxia/ OMIM 
#229300; AT, ataxia telangiectasia/ OMIM #208900; AOA, ataxia with oculomotor apraxia/ OMIM 
#208920; ATLD, ataxia-telangiectasia-like disorder/ OMIM #604391; SCAN, spinocerebellar ataxia 
with axonal neuropathy/ OMIM #607250; JBTS, Joubert syndrome/ OMIM #614464 ; AVED, ataxia 
with isolated vitamin E deficiency/ OMIM #277460; CTX, Cerebrotendinous xanthomatosis/ OMIM 
#213700; FXTAS, fragile X-associated tremor/ataxia syndrome/ OMIM #300623; MELAS, 
mitochondrial encephalopathy, lactic acidosis and stroke-like episodes/ OMIM #540000; MERRF, 
myonucleus epilepsy with ragged-red fibres/ OMIM #545000; NARP, neuropathy, ataxia and retinitis 
pignemtosa/ OMIM #551500. 
The focus of this thesis concerns one of these rare ARCA diseases caused by recessive mutations 
in STUB1 encoding the CHIP ligase protein. 
1.7 Autosomal Recessive Cerebellar Ataxia (ARCA): the current state of 
affairs 
The recessively inherited group of cerebellar ataxias is characterized by an early onset and 
gradual worsening of gait and balance with the development of hypotonia or excessive 
clumsiness over months and years. Friedrich Ataxia (FA) with the estimated prevalence of 2-
4/100,000 is known to be the most frequent type of ARCA. This is followed by Ataxia 
Telangiectasia (AT) (1-2/100,000) and early onset cerebellar ataxia with retained tendon reflexes 





development of the whole exome sequencing (WES) approach. WES is a powerful tool for 
studying those rare Mendelian disorders for which the causative mutations could not be identified 
by conventional methods such as linkage mapping and candidate gene sequencing. Exome 
sequencing allows for a quick, cost-efficient sequencing of the entire protein-coding region of the 
genome through parallel sequencing of an enriched, amplified library of short DNA fragments 
containing approximately 3-10 billion base pairs (Gbp) of data. Candidate causal variants called 
by mapping and alignment of the sequencing data will be filtered subsequently against a set of 
polymorphisms available in public databases, and a minimum number of high priority variants 
will be detected for each individual, among which, mutations leading to dominant and recessive 
disorders are expected to be seen [55, 56].  
 
Table 1.7.1 Classification of ARCA based on molecular pathogenesis. IOSCA, infantile onset 
spinocerebellar ataxia/ OMIM# 271245; SANDO, sensory ataxic neuropathy, dysarthria and 
ophthalmoparesis/ OMIM #607459; MIRAS, mitochondrial recessive ataxia syndrome; ARSACS, 
autosomal recessive spastic cerebellar ataxia of Charlevoix-Saguenay/ OMIM #270550; MSS, Marinesco-





Different types of ARCAs can be distinguished based on the underlying disease mechanism: (1) 
mitochondrial dysfunction, (2) DNA repair deficiency, (3) mis-localization of synaptic 
myonuclei, (4) altered function of calcium-mediated chloride channels, (5) altered vascular 
trafficking, and (6) protein misfolding and chaperone dysfunctions. Common diseases and 
causative mutations related to each pathway are listed in Table 1.7.1. 
Some of these mutations are considered to be very rare, being restricted to isolated populations or 
single families, like mutations in C10orf2, TDP1, and KIAA0226 [51]. In addition, recessive 
mutations in STUB1 (encoding CHIP) have been discovered lately to cause another subtype of 
ARCA named autosomal recessive spinocerebellar ataxia-16 (SCAR16) in a limited number of 
families. These mutations affect different domains of CHIP, mostly through the substitution of a 
single amino acid in the protein sequence (missense mutations) (Figure 1.7.1) [30, 49, 57-63]. 
 
 
              
Figure1.7.1 STUB1 mutations and corresponding CHIP protein domains. The locations of all the 
mutations associated with SCAR16 are specified. The inserted tables indicate the respective nucleic acid 
and amino acid change for each mutation. This figure is adapted from [49]. STUB1 reference sequence 
(RefSeq) = NM_005861.3. 
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2. Aims of the study 
This project is based on identification of three mutations in STUB1 in two families with SCAR 16 
using a combination of homozygosity mapping and exome sequencing by our group. These 
mutations include p.E28K, p.N656S, and p.K144* [30]. Recent studies have characterized the 
molecular properties of these mutations to some extent, yet more investigations are required to 
achieve a clear picture of changes in CHIP structure and function under the effect of different 
mutations. Thus, the two mutations E28K and N65S together with four additional mutations on 
CHIP were selected for further analysis. The location of each mutation is illustrated in Figure 2.1. 
                             
Figure 2.1 The position of each selected mutation is shown in the 3D structure of the dimeric CHIP 
with colorful spheres. Mutations E28K (dark gray) and N65S (light gray) are located at the TPR domain 
(orange). Mutations K145Q (pink) and M211I (red) are placed at the central domain (light blue) and the 
two last mutations S236T (purple) and T246M (dark blue) are positioned in the U-box domain (green) of 
the protein. This figure was created by using PyMOL software (https://www.pymol.org). 
The overall aim of this study was to characterize the molecular properties of mutations in STUB1 
-a newly identified gene responsible for SCAR 16, following the specific objectives: 
1) To study in vitro ubiquitination activity of the wild type and mutant encoded CHIP proteins. 
2) To check the effect of mutations on CHIP protein susceptibility to limited proteolysis, in 
vitro. 
3) To identify different conformational states of mutant CHIP proteins and compare them with 
the wild type, in vitro. 
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4) To study the secondary structure and thermal stability of CHIP proteins for both wild type 
and mutant forms, in vitro. 
5) To investigate if the expression level of exogenous CHIP is affected by the mutations, in 
cellulo. 
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3. Materials and Methods 
3.1 Site-directed mutagenesis 
The QuickChange® XL Site-directed Mutagenesis Kit (Agilent Technologies, Santa Clara, 
California, USA) was used to introduce three specific mutations including p.K145Q (c.433A>C), 
p.M211I (c.633G>A), and p.S236T (c.707G>C) into the WT STUB1 cDNA (reference sequence: 
NM_005861.3, [64]) in the mammalian expression vector pcDNA3.1-V5/HisB and bacterial 
expression vector pETM-41-MBP/His [30]. Forward and reverse primers (provided by Sigma-
Aldrich, Missouri, USA) are listed in Table 3.1.1. Mutant plasmids for three mutations including 
p.E28K (c. 82C>G), p.N65S (c.194 C>A), and p.T246M (c.737C>T) were previously constructed 
[30] and, therefore, were not included here. 
Table 3.1.1 Mutagenesis primers 
Primer Sequence 
K145Q Forward 5´-GCT-GTT-CCA-GCG-CTG-CTT-CTT-CGC-GAT-TCG-3´ 
K145Q Reverse 5´-CGA-ATC-GCG-AAG-AAG-CAG-CGC-TGG-AAC-AGC-3´ 
M211I Forward  5´AAA-AAG-CTC-GTC-TAT-GTC-CGC-CAT-GTA-CTT-GTC-GT-3´ 
M211I Reverse 5´-ACGACA-AGT-ACA-TGG-CGG-ACA-TAG-ACG-AGC-TTT-TT-3´ 
S236T Forward 5´-CCG-CAT-CAG-CTC-AAA-GGT-GAT-CTT-GCC-ACA-CAG-3´ 
S236T Reverse 5´-CTG-TGT-GGC-AAG-ATC-ACC-TTT-GAG-CTG-ATG-CGG-3 
 
Each tube for a mutagenesis reaction was prepared by adding 1 µl of PfuUltra High Fidelity DNA 
polymerase to 50 µl master mix containing 5 µl 10x reaction buffer, 10 ng plasmid DNA, 125 ng 
forward and reverse primers, 1 µl dNTP mix, 3 µl QuickSolution
TM
 Reagent, and MilliQ water. 
The mutagenesis was carried out by running Polymerase Chain Reaction (PCR) (Gene Amp
®
 
PCR Systems 9700, Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachusetts, 
USA) for the control and sample reactions using the program: 
 
Pre-denaturation 95 °C 1 min  
Denaturation 95 °C 50 sec  
Annealing 60 °C 50 sec x18 cycles 
Extension 68 °C 6 min  
Final Extension 68 °C 7 min  
End 4 °C ∞  
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Following the PCR, the tubes were cooled down to ≤37 °C for 2 min on ice, and the parent DNA 
plasmids were digested by adding 1 µl of diphosphopyridine nucleotidase Dpn I restriction 
enzyme directly to the tubes and incubating at 37 °C for one hour (BINDER Laboratory 
Incubator, Tuttlingen, Germany). The mutant DNA plasmids were further transformed into the 
bacterial competent cells for sequencing and analysis as described in the sections below. 
 
3.2 Transformation of XL10-Gold competent cells 
The XL10-Gold ultracompetent cells were gently thawed on ice and prepared in 45 µl aliquots 
for transformation with the control and mutated vectors. Two µl of XL10-Gold β-
mercaptoethanol mix (β-ME) was first added to the cells, swirling every 2 min during a 10 min 
pre-incubation on ice. The cells were then mixed with 2 µl of DpnI-treated DNA plasmid and 
incubated for 30 min on ice. Transformation was completed by subjecting the cells to a 30 sec 
heat-pulse in a water bath at 42 °C, and followed by a further 2 min incubation on ice. A volume 
of 500 µl pre-heated S.O.C Medium (Sigma-Aldrich) was added to the transformed cells, and 
they were grown at 37 °C for one hour with agitation (Innova 4300 Incubator Shaker, Thermo 
Fisher Scientific). After incubation, 250 µl of the cells were spread on room-tempered 
ImMedia
TM 
KanAgar (for pETM-41 plasmid transfected cells) and ImMedia
TM 
AmpAgar (for 
pcDNA3.1-V5/HisB plasmid transfected cells) LB-agar plates (Invitrogen, Thermo Fisher 
Scientific). Colonies were analyzed and selected after an overnight incubation at 37 °C. 
 
3.3 Colony PCR and sequencing 
A few colonies were selected and screened by sequencing to confirm that they contained 
plasmids with the desired mutations. Each colony was suspended in 10 µl of MilliQ water of 
which 1 µl was used for the PCR reaction. The PCR mixture was prepared in a final volume of 20 
µl by adding 1 µl 360 GC Enhancer (Thermo Fisher Scientific), 1 µl of each forward and reverse 
primer (Sigma-Aldrich) and 1 µl of the colony suspension to 10 µl of AmpliTaq Gold® 360 
Master Mix (Thermo Fisher Scientific). A negative control tube was prepared by adding 1 µl of 
MilliQ water in substitution for the bacterial suspension to the reaction mixtures. The PCR was 
conducted with the following thermocycling conditions:  
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Pre-denaturation 94 °C 10 min  
Denaturation 94 °C 30 sec  
Annealing 58 °C 30 sec x35 cycles 
Extension 72 °C 30 sec  
Final Extension 72 °C 7 min  
End 4 °C ∞  
 
For all the colonies and control reactions, T7 Promoter Primer was used as the forward primer. In 
addition, BGH and T7 Terminator primers were used as the reverse primer for pcDNA3.1-V5/His 
and pETM-41 mutant plasmids, respectively. For primer sequences, see Table 3.3.1. 
After the PCR, 5 µl of each reaction was mixed with 1 µl of DNA Gel  loading Dye (6x) (Thermo 
Fisher Scientific) and  analyzed for the presence of the amplified DNA fragment by agarose gel 
electrophoresis using 1 kbp DNA Ladder (New England BioLabs, Massachusetts, USA) as 
described in Section 3.15.1.  
Colonies with correct DNA size were subjected to DNA sequencing. In this step, the additional 





 (Sigma-Aldrich) to 5 µl of PCR product in new sets of tubes using the PCR- 
program: 
 
1 94 °C 15 min 
2 80 °C 15 min 
End 4 °C ∞ 
  
This was continued with another PCR process in which 1 µl of the previous PCR product 
together with 0.5 µl of different internal STUB1 primers covering the area of mutations (Table 
3.1.1) were added to an 8.5 µl mixture containing 2 µl of 5x Sequencing Buffer (Applied 
Biosystems), 1 µl of Big Dye Terminator v1.1 cycle sequencing buffer (Applied Biosystems) and 
MilliQ water. The following PCR-program was used in this step: 
 













End 4 °C ∞   
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Sequencing was performed by the DNA sequencing facility core (Center for Medical Genetics 
and Molecular Medicine, Haukeland University Hospital) using an Applied Biosystems 3730 
capillary sequencer (Applied Biosystems) and the results were analyzed by Finch TV v.1.4.0 
software (Geospiza Inc., Seattle, Washington, USA). 


















3.4 Plasmid purification 
Those bacterial colonies in which the desired mutations were verified by sequencing were 
selected and grown for plasmid purification using QIAfilter
TM
 Plasmid Maxi Kit (25) (Qiagen, 
Hilden, Germany). The first cultures were prepared by an 8 hour incubation of the bacterial 
colony in 5 ml LB Medium containing one LB Broth 1.1 G Tablet (Sigma-Aldrich) per 50 ml 
MilliQ water and 100 µg/ml kanamycin. Five hundred ml of the same medium was then 
inoculated with 500 µl of the grown culture and incubated overnight at 37 °C with agitation. On 
the next day, bacterial cultures were centrifuged at 4600 rpm for 40 min at 4 °C (Multifuge 3S-R, 
Thermo Fisher Scientific), and the resulting pellets were completely resuspended in 10 ml buffer 
P1 containing 100 µg/ml RNAase A and 1:1000 LyseBlue reagent
®
. The solution was then mixed 
well with 10 ml buffer P2 and incubated for 5 min at room temperature. Using LyseBlue reagent, 
the lysate turned blue after sufficient mixing. In order to precipitate non-plasmid material, 10 ml 
of pre-chilled buffer P3 was added to the lysate and mixed immediately until a homogeneous, 
colorless suspension was appeared. The lysate was poured into the barrel of the QIAfilter 
Cartridge and incubated for 10 min at room temperature. Thereafter, the cap was removed from 
the cartridge and the cell lysate was gently filtered into the QIAGEN-tip that had previously been 
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equilibrated with 10 ml buffer QBT. The tip was washed twice with 30 ml buffer QC, and further 
eluted with 15 ml buffer QF. To precipitate DNA, 10.5 ml room-temperature Isopropanol (Arcus, 
Oslo, Norway), was added to the eluted samples, followed by 1 hour centrifugation at 4600 rpm 
at 4 °C. DNA pellets were then washed with 5 ml room tempered 70% Ethanol (Sigma-Aldrich) 
and centrifuged at 4600 rpm for 30 min at 4 °C. The supernatant was carefully removed and the 
pellets were air-dried for 15 min before dissolving in 250 µl Tris-EDTA (TE) buffer  (1 M Tris-
HCl, pH 8.0, 0.5 M EDTA, pH 8.0). The DNA concentration in the samples was measured using 
Nanodrop ND-1000
TM 
(Saveen Werner, Limhamn, Sweden), and the samples stored at 20 °C.  
Finally, the entire sequence of STUB1 cDNA was verified by DNA sequencing, using the same 
primers as used before (Section 3.3, Table 3.3.1). Sequencing was performed in an Applied 
Biosystems 3730 capillary sequencer at the DNA sequencing facility core at the Center for 
Medical Genetics and Molecular Medicine at Haukeland University Hospital. 
 
For in vitro recombinant protein studies 
 
3.5 Recombinant protein production 
 
3.5.1 Transformation of BL21 bacterial cells with recombinant vectors 
WT and mutant CHIP cDNA in His6-MBP-tagged vectors pTEM-41 were transformed into 
BL21-CodonPlus (DE3)-RP competent cells (Agilent Technologies). One µl plasmid was added 
to 50 µl BL21 cells and incubated on ice for 30 min. In order to increase transformation 
efficiency, 2 µl of a 1:10 dilution of the XL10-Gold β-mercaptoethanol mix (Agilent 
Technologies) had been previously added to the cells and gently swirled for 10 min on ice. The 
cells were then heat-pulsed in a water bath at 42 °C for 20 sec, and placed on ice for another 10 
min. Transformed cells received 450 µl of pre-heated S.O.C medium and were incubated with 
shaking (225 rpm) at 37 °C for one hour. Fifty µl of the cell suspension together with 50 µl of 
S.O.C medium was further plated out on ImMedia
TM 
KanAgar LB-agar plates, and incubated 
overnight at 37 °C. Colonies were analyzed and selected the next day. 
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3.5.2 Recombinant protein expression in BL21 cells (E.coli) 
A start culture was prepared by picking a single colony of transformed BL21 cells and adding it 
to 20 ml LB medium containing 100 µg/ml kanamycin, 0.2% filtered glucose and 50 µg/ml 
chloramphenicol (Sigma-Aldrich). The culture was incubated overnight at 37 °C with agitation. 
Five hundred ml of the same medium was inoculated with 5 ml of the overnight culture and left 
to incubate at 37 °C with shaking until it had grown to 0.6-0.8 OD at 600 nm (measured in a 
spectrophotometer; PerkinElmer, Massachusetts, USA) which is an ideal value of cell density for 
initiating protein expression based on the Qiagen protocol for high-level expression and 
purification of 6X His-tagged proteins. After adding Isopropyl ß-D-1-thiogalactopyranoside 
(IPTG) (GE healthcare, little Chalfont, UK) to a final concentration of 0.5 mM, the cells were 
induced to express recombinant protein during an overnight incubation at 25 °C with agitation 
(Innova 4230 Refrigerated Incubator Shaker, Thermo Fisher Scientific). In order to check 
whether protein expression had been sufficiently induced before proceeding with protein 
purification, 1 ml culture was removed before and after IPTG addition and centrifuged at 3000 
rpm for 2 min (Centrifuge 5424, Eppendorf, Hamburg, Germany). The bacterial pellet was 
further resuspended in 400 µl MilliQ water, and a 10 µl aliquot was analyzed by SDS-PAGE and 
Coomassie blue staining as described in Sections 3.15.2 and 3.16.1. 
 
3.5.3 Recombinant protein purification 
The overnight culture was centrifuged at 4000x g for 45 min at 4 °C. Bacterial pellets were 
dissolved in 5 ml/g wet weight lysis buffer (50 mM NaH2PO4.H2O, 300 mM NaCl, 10 mM 
Imidazole, 20 mM 2-Mercaptoethanol, 0.1% Tween-20, pH 8) and sonicated 10 times (each for 
20 sec with 10 sec cooling time in-between) on ice at 300-400 W power output (VirSonic 300, 
VirTis, Gardiner, USA). Aliquots of 2 ml harvested cells were further centrifuged at 15000x g for 
40 min at 4 °C (Centrifuge 5417C, Eppendorf), and the supernatant was collected. In order to 
purify His-MBP-tagged proteins from the protein pool of the cells, 1 ml of Ni-NTA Agarose 
Nickel Resin (Qiagen, Venlo, Netherlands) was added as a 50% slurry in lysis buffer to the 
supernatant and left rotating for 1 hour (Labinco Beher B.V., Breda, Netherlands). The unbound 
material was removed by centrifugation at 1500x g for 2 min, and the protein-bound resin was 
loaded to the Micro Bio-Spin™ Size Exclusion Spin Columns (Bio-Rad Laboratories, Hercules, 
California, USA) and washed with 1 ml washing buffer (50 mM NaH2PO4.H2O, 300 mM NaCl,
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20 mM Imidazole, 20 mM 2-Mercaptoethanol, 0.1% Tween-20, pH 8) three times. The resin was 
centrifuged at 1500x g after each wash. Finally, 500 µl of elution buffer (50 mM NaH2PO4.H2O, 
300 mM NaCl, 250 mM Imidazole, 20 mM 2-Mercaptoethanol, 0.1% Tween-20, pH 8) was 
added and allowed to pass through the column by gravity to elute His-MBP-tagged proteins. The 
elution step was repeated three times and the protein fractions were collected in separate 
Eppendorf tubes each time. 
 
3.5.4 Determination of recombinant protein concentration  
The protein concentrations were measured on a Nanodrop ND-1000
TM 
using the molar extinction 




) for MBP-CHIP, decided according to the method of 
Gill and von Hippel [65]. Blank measurements were made with elution buffer, and a minimum of 
two parallel samples were measured for each protein sample. 
 
3.5.5 Recombinant protein buffer exchange 
Using Zeba™ Spin Desalting Columns (Thermo Fisher Scientific), the elution buffer was 
changed to the suitable buffer for protein storage (100 mM Hepes, pH 8, 5 mM DTT, 100 mM 
NaCl, 10% Glycerol). The columns were first put in collection tubes and centrifuged at 1000x g 
for 2 min with twisted-off bottom closures and loosened caps. The storage buffer was next added 
to the columns and centrifuged at 1000x g for another 2 min. This step was repeated 4 times to 
ensure optimal buffer exchange. Finally, the columns were placed in new collection tubes and 
protein samples were applied to the center of the compact resin bed. After 2 min centrifugation at 
1000x g, the MBP-CHIP proteins were collected in the new storage buffer. The concentrations of 
the protein samples were measured once again by Nanodrop ND-1000
TM
 using the storage buffer 
as the blanking solution. 
 
3.6 Separation of MBP tags by TEV protease 
In order to generate CHIP, the Hisx6-MBP-tagged proteins were subjected to TEV protease 
cleavage at 25 °C. The optimal conditions for cleavage was decided between three different ratios 
of MBP-CHIP protein to TEV 10:1, 20:1, 50:1 (by mass), and two different incubation periods of 
1 and 2 hours. For this, the protein concentrations of TEV Protease (produced from pTH24 vector 
with C-terminal His tag, a kind gift from Rune Kleppe, Dept. of Biomedicine, University of
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Bergen) and WT MBP-CHIP fusion protein were first measured on Nanodrop ND-1000
TM
, and 
the proper volumes for each protein solution were decided accordingly. The samples were then 
analyzed for complete cleavage by SDS-PAGE and Coomassie staining as described in Sections 
3.15.2 and 3.16.1. 
 
3.7 CHIP ubiquitination activity assay 
In vitro ubiquitination activity assay was set up for both MBP-fusion and MBP-cleaved CHIP 
recombinant proteins. The reactions were prepared in the total volume of 20 µl, containing 2.5 
µM (MBP-) CHIP (E3), 2.5 µM UbcH5c (E2) (Boston Biochem, Cambridge, Massachusetts, 
USA), 0.05 µM Ube1 (E1, a kind gift from Lise Bjørkhaug Gundersen, KG Jebsen Center for 
Diabetes Research, University of Bergen), 250 µM Ubiquitin (Boston Biochem), and 0.8 µM 
His-HSPA8 (HSC71) Recombinant Human Protein (Life Technologies AS, Thermo Fisher 
Scientific) in an ubiquitination buffer (50 mM Tris HCl, pH 7.5, 0.6 mM DTT, 2.5 mM Mg-
ATP). MilliQ water was added at the end to reach the final solution volume. A one hour 
incubation at 37 °C was allowed to complete each reaction before the samples were placed on ice. 
Protein samples were explored for self- and Hsc70-ubiquitination activities by Western blot 
analysis and SDS-PAGE electrophoresis (see Sections 3.17 and 3.15.2), using primary antibodies 
against CHIP (LS-C137950, LifeSpan Bioscience, Seattle, WA, USA) and Hsc70 (ADI-SPA-
815-F, Enzo Life Sciences, NY, USA), respectively. The goat anti-rabbit IgG-HRP (sc-2030, 
Santa Cruz Biotechnology, Dallas, Texas, USA) antibody was used as the secondary antibody in 
both cases. 
 
3.8 Limited proteolysis assay 
Limited proteolysis assay was carried out using 30 µg of the CHIP recombinant proteins 
separated from the MBP tag by TEV protease beforehand (Section 3.6).  To start proteolysis, 
trypsin was added to each protein sample at a CHIP to trypsin ratio of 1:600 (by mass) in a 100 µl 
reaction mixture (50 mM NaCl, 20 mM Hepes, and 2 mM DTT) and incubated at 25 °C over a 30 
min period of time. The reactions were terminated at different time points (0, 5, 10, 20, 30 min) 
by adding 18.5 µl of the reaction mixture to 5 µl NuPAGE LDS Sample Buffer (4X) (Thermo 
Fisher Scientific), 1.4 µl  NuPAGE Sample Reducing Agent (10X) (Thermo Fisher Scientific), 
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and 1 µl of the trypsin inhibitor (previously prepared using a protease to inhibitor mass ratio of 
1:1.5) on ice. Finally, all the samples were analyzed by SDS-PAGE and SYPRO Ruby staining as 
described in Sections 3.15.2 and 3.16.2. Full-length CHIP protein gel bands were quantified by 
Multi Gauge v3.0 software (Fujifilm, Tokyo, Japan) and Image Processing and Analysis in Java 
(Image J, National Institutes of Health, Bethesda, Maryland, USA) software. Rates of proteolysis 
were further plotted using Microsoft
®
 Office Excel 2010 (Microsoft
 ®
 Corporation, Redmond, 
WA, USA). 
 
3.9 CHIP protein purification on amylose resins 
To remove MBP tag from the CHIP protein solution, ~400 µg of the WT MBP-CHIP fusion 
protein was tested for amylose purification after being separated from MBP by TEV protease 
cleavage (Section 3.6). The Amylose Resin stored in 20% Ethanol (New England Biolabs) was 
prepared in a 200 µl volume as a 50% slurry with the protein storage buffer (for the buffer 
composition, see Section 3.5.5). The MBP-cleaved protein sample was added to the resins, and 
rotation was performed for 30 min at 4 ˚C. Next, the sample was transferred to the Micro Bio-
Spin™ Size Exclusion Spin Columns, and washed twice with 150 µl storage buffer.  The flow-
through was collected in separate Eppendorf tubes each time for further analysis by SDS-PAGE 
and Coomassie blue staining as described in sections 3.15.2 and 3.16.1. For a complete recovery 
of the flow-through, the resin was centrifuged for 2 min at 1500x g following each wash. 
 
3.10 Purification of CHIP by size-exclusion chromatography  
The purification of CHIP from MBP-CHIP protein solution was tested by size-exclusion 
chromatography using BioLogic DuoFlow
TM 
Medium-Pressure Chromatography System (Bio-
Rad Laboratories, Hercules, California, USA) after it had been separated from MBP tag by TEV 
protease cleavage (see Section 3.6). Two hundred µg of the WT MBP-cleaved CHIP protein was 
injected in a final volume of 600 µl protein solution to the top of the Superdex 200 Increase 
10/300 GL (GE Healthcare) chromatography column, passing through the column at a constant 
flow rate of 0.5 ml/min for 50 min at 4 °C (performed under supervision). To avoid possible 
aggregation, the protein sample was centrifuged for 10 min at 16000 rpm at 4 °C before injection. 
In addition, the column was equilibrated overnight with two column volumes (50 ml) of a buffer
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containing 20 mM NaH2PO4, pH 7.4 before starting separation. The purification process was 
repeated twice using different conditions so that optimized purification among the three trials 
could be achieved. For the second chromatography, the amount of protein was increased by as 
much as 2 mg, with a flow rate of 0.25 ml/min through the column that was equilibrated 
overnight by using another buffer composition (50 mM NaH2PO4, 5 mM DTT, pH 7.2). The last 
chromatography was performed using Superdex 75 Increase 10/300 GL (GE Healthcare) as the 
gel-filtration column material. A buffer containing 100 mM Hepes, pH 8, 5 mM DTT, 100 mM 
NaCl was used for column equilibration, and the same amount of protein (2 mg) passed through 
the column at a flow rate of 0.5 ml/min. At the end of each run, using BioLogic DuoFlow 
software (Bio-Rad Laboratories),  those fractions corresponding to the recorded elution peaks 
were collected and analyzed for protein content with SDS-PAGE and Coomassie blue staining as 
described in Sections 3.15.2 and 3.16.1. 
 
3.11 Oligomerization study of MBP-CHIP fusion proteins  
Different oligomeric states of the WT and mutant MBP-CHIP fusion proteins were studied by 
gel-filtration analysis, using the BioLogic DuoFlow
TM 
Medium-Pressure Chromatography 
System. One mg of MBP-CHIP protein was run on the Superdex 200 Increase 10/300 GL 
chromatography column at a constant flow rate of 0.3 ml/min as described in Section 3.10. The 
column was equilibrated overnight with 50 ml phosphate buffer (20 mM NaH2P04, pH 7.4) in 
advance. BioLogic DuoFlow software was used to monitor the elution peaks at the end of each 
run. Protein fractions associated with the recorded peaks were collected and analyzed using SDS-
PAGE and Coomassie blue staining as described in Sections 3.15.2 and 3.16.1. 
 
3.12 Circular Dichroism (CD) spectroscopy 
The secondary structure and thermal unfolding of MBP-CHIP fusion proteins (WT and mutants) 
as well as MBP protein were monitored with a spectropolarimeter. All the samples were prepared 
at a concentration of 6 µM in a CD compatible buffer containing 10 mM potassium phosphate 
(pH 7.4), and 100 mM sodium fluoride. The buffer was exchanged following the protocol 
provided by Zeba™ Spin Desalting Columns (see Section 3.5.5). Protein concentrations were 
precisely determined by the protein A (280) method, in which the protein absorption at 280 nm was 
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measured in a spectrophotometer and used to calculate the protein concentration (mg.ml
-1
), from 
the following formula:  
C=A/Ɛ (0.1%) * I 
Where Ɛ is the extinction coefficient number for a 0.1% protein solution (1.224 for MBP-CHIP 
and 0.512 for MBP, given by [66]), and I is the cuvette path length in cm. The protein absorbance 
was measured over the range of 220-340 nm, using a 1 cm absorption cuvette (Hellma Analytics, 
Müllheim, Germany), and Agilent 8453 UV-Visible spectrophotometer (Agilent Technologies) at 
a temperature maintained at 20 °C, controlled by a Hewlett Packard 89090A Peltier Temperature 
Controller (Hewlett-Packard, California, USA).  
Far-UV spectra and thermal denaturation analysis were performed for 300 µl of each protein 
sample in a 1 mm quartz cell (Hellma Analytics), using the Spectra Manager software v.1.53.04 
(Jasco Corporation, MD21601, USA) and a J-810 Jasco spectropolarimeter equipped with a 
CDF-426S Peltier element for temperature control (Jasco Products Company, Oklahoma City, 
Oklahoma, USA). The initial nitrogen flow rate of 10 l/min was used to measure the far-UV 
spectra in the wavelength range between 185–260 nm at a scan rate of 50 nm/min at 20 °C. Four 
scans were accumulated for each spectrum and averaged.  The final spectra were recorded after 
buffer-subtraction. Thermal denaturation profiles were obtained at 5 l/min nitrogen flow rate 
through recording the ellipticity at 222 nm as a function of temperature in the range 20–90 °C 
with a scan rate of 40 °C per hour. Online Dichroweb software (Dr. L. Whitmore, University of 
London, London, UK) was used to calculate secondary structure content of proteins from their 
far-UV spectra [67]. Figure 3.12.1 demonstrates a typical thermal unfolding curve for a globular 
protein, consisting of at least one melting transition region (two-state unfolding pattern) where 
the unfolded (U) form of protein is resulted from denaturation of the native (N) protein at a 
temperature reported as transition midpoint temperature or Tm. 
 Figure 3.12.1 Two-state thermal unfolding profile of 
globular proteins. The transition region indicates that the 
native protein unfolds while the temperature is increasing. 
Tm or denaturation midpoint is defined as the temperature at 
which both the unfolded (U) and folded (N) states of protein 
are presented equally at equilibrium. 
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For in cellulo protein studies 
 
3.13 Cell cultivation 
Human Embryonic Kidney 293 (HEK293) (ATCC, Manassas, Virginia, USA) cells were cultured 
in Dulbecco’s modified eagles medium (DMEM) (4.5 g/L glucose) (Invitrogen) containing 10% 
heat-inactivated FBS (Invitrogen) and 0.05 mg/ml of active Gentamycin
®
 (50 mg/ml) (Life 
technologies). The cells were grown at 37 °C with 5% CO2 (Steri-Cycle CO2 Incubator, Thermo 
Scientific); using 25 cm
2




 Delta Surface cell culture flasks (Thermo 
Scientific). The media was changed every second day. All cell procedures were carried out in a 
Scanlaf Mars Flowbench (Labogene ApS, 3540 Lynge, Denmark), and all the volumes 
correspond to 75 cm
2
 flasks, if not otherwise stated. 
 
3.13.1 Thawing  




, Thermo Scientific) in a 
water bath (Lauda Aqualine water bath) (97912 Lauda-Konigshofen, Germany) at 37 °C for 2-3 
min. To the thawed cells in a 15 ml Falcon tube, 4 ml growth media was added, and the tube was 
centrifuged (Heraeus Megafuge 1.0R centrifuge) (DJB Labcare Ltd., Buckinghamshire, UK) for 
6 min at 1300 rpm. The cell pellet obtained was resuspended in 5 ml media and transferred to a 
25 cm
2
 flask for further growth. 
 
3.13.2 Splitting 
Cells were passaged into new flasks after reaching 80-90% confluency. The media was removed 
and the cells were detached from the flask surface after a quick wash with 10 ml PBS 
(Invitrogen). Two ml 0.05% Trypsin-EDTA (Invitrogen) was used to trypsinize the cells. After 5 
min incubation at room temperature cells were monitored under the microscope for complete 
detachment. Trypsin was next neutralized by adding 8 ml media to the flask, and resuspended 
cells were transferred into new flasks together with fresh growth media in a total volume of 10 
ml, using various ratios of cells to media. 
 




In order to freeze cells, a flask of ~80% confluent cells was washed with 10 ml PBS and 
trypsinized as described in Section 3.13.2. Following trypsin inactivation, the cell suspension was 
centrifuged in a 15 ml Falcon tube for 5 min at 1300 rpm. The pellet was resuspended in 4 ml 
BAMBANKER
TM 
serum-free cell freezing medium (Lymphotec, Inc., Tokyo, Japan) and 
aliquoted into four cryotubes. The tubes were kept at room temperature for 20 min before a long-
term freezing at -80 °C. 
 
3.14 Determination of exogenous protein expression level 
 
3.14.1 Cell transfection 
Transiently transfected HEK293 cells expressing WT and mutant CHIP were prepared by using 
Metafectene. Cells were seeded into Nucleon
TM
 Delta Surface 6-well plates (Thermo Scientific) 
at a concentration of one million cells per ml (10
6
 cells/ml), counted by using a Scepter
TM
 
Handheld Automated Cell Counter (Merk Millipore, Massachusetts, USA). Each well was coated 
with 1 ml Poly-L-Lysine 0.01% solution (Sigma-Aldrich) (1:10 diluted in PBS) and washed with 
PBS three times before seeding. One million cells (1 ml) were added to 1 ml of media (DMEM 
without gentamycin) in each well, and grown overnight at 37 °C. In order to transfect the cells, 3 
µg of each WT and mutant STUB1 pcDNA/V5-HisB plasmid as well as a negative control 





75 µl 1x Easy
+
 buffer (Biontex Laboratories GmbH, Martinsreid, Germany), and incubated for 15 
min at room temperature. Cells were further added by 50 µl of the prepared mixture in each well, 
and grown at 37 °C overnight. The media was changed to the one containing gentamycin 
antibiotic after 4-6 hours to avoid possible contamination. Cells were collected and lysed the 
following day as is described in the next section. 
 
3.14.2 Cell lysis 
Cells were washed twice with 1 ml cold PBS prior to being lysed. Two hundred µl Pierce
® 
RIPA 
buffer (Thermo Scientific) containing 1x Halt Protease Inhibitor Cocktail (PIC) (100X) (Thermo 
Scientific) was used to lyse the cells in each well. Cell lysates were next collected and transferred 
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into Eppendorf tubes by using a cell scraper (TPP Techno Plastic Products AG, Trasadingen, 
Switzerland). This was followed by a 15 min centrifugation at 15000x g whereby a cleared lysate 
was achieved and stored at -80 °C until further use (see the next section). 
 
3.14.3 Determination of cellular protein concentration 
The Pierce
TM 
Bicinchronic acid (BCA) protein assay kit (Thermo Scientific) was used to 
determine the concentrations of exogenously expressed proteins in HEK293 cell lysate fractions 
by measuring absorbance at 562 nm (A (562)). Measurements were performed in 96-well 
microplates (Greiner Bio-One GmbH, 72636 Frickenhausen, Germany) on a Synergy
TM
 HT plate 
reader (Bio Tek Instruments, Inc., VT, USA), using BSA standards and working reagents. 
Standard reagents were prepared by diluting the BSA standard stock solution in RIPA buffer to a 
series of concentrations from 0 to 2000 µg/ml according to the supplier’s protocol. The working 
reagent was made by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B, and 200 
µl volume was added to 25 µl of each unknown and standard sample replicates in the microplate 
wells. Samples were mixed on a plate shaker for 30 second and incubated for 30 min at 37 °C. 
Protein absorbance was measured two times for both BSA standards and protein samples in 
parallel, and the average concentration for each sample was obtained from a linear regression 
standard curve using the Gen5 Microplate Reader and Imager Software (Bio Tek). 
Cell lysates were next analyzed by SDS-PAGE (see Section 3.15.2) and immunoblotting (see 
Section 3.17), using a primary antibody against CHIP and secondary antibody against rabbit. 
Samples were loaded in volumes equal to 10 µg cellular protein. To provide an internal loading 
control, the membrane was stripped and blotted against actin as described in Section 3.17.3. A set 
of antibodies against actin (sc-1615, Santa Cruz Biotechnology) and rabbit anti-goat IgG-HRP 
(sc-2768, Santa Cruz Biotechnology) was used in this step. CHIP protein bands were finally 
quantified using Multi Gauge and Image J softwares, and were finally normalized against actin.  
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For protein detection and analysis  
 
3.15 Electrophoresis 
*If not otherwise stated, all the materials in the electrophoresis techniques were purchased from 
the Thermo Fisher Scientific Company. 
 
3.15.1 Agarose gel electrophoresis 
For separation and analysis of DNA fragments by molecular weight, agarose gel electrophoresis 
was performed using 50 µl of 1% (w/v) Nusieve agarose gel placed in 1x TBE buffer (Sigma-
Aldrich). Three drops of ethidium bromide were added to the gel prior to solidification to 
visualize the bands on the gel. Six µl of loading sample was prepared by mixing 3 µl of DNA 
samples and DNA Gel Loading Dye (6x) to a final concentration of 1x, and loaded onto the gel 
along with 5 µl of DNA standard size marker (New England BioLabs). Following electrophoresis 





System (BioRad Laboratories). 
 
3.15.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Using sodium dodecyl sulfate polyacrylamide gels, proteins were linearized and separated by size 
during SDS-PAGE. Ten µl of protein samples were added with NuPAGE
®
 LDS Sample Buffer 
(4x) and NuPAGE
®
 Sample Reducing Agent (10x) to a final concentration of 1x followed by 
denaturation at 70 °C for 10 min. Maximum recommended volumes of the denatured proteins 
were applied together with 5 µl of SeeBlue
®
 Plus2 Pre-stained Protein Standard ladder on the 
wells of precast Bolt™ 10% Bis-Tris Plus Gels. In order to prevent sample reoxidation, and to 
maintain reducing conditions, 500 µl of Nupage
®
 Antioxidant was added to the 1x MOPS 
running buffer (prepared in a total volume of 1 liter NuPAGE
®
 MOPS SDS Running Buffer 




 Mini-Cells. The gel was run at 
200 V for 1 hour, and the bands were visualized using the SimplyBlue SafeStain Coomassie 
staining technique as described in Section 3.16.1. 
 
3.15.3 Native polyacrylamide gel electrophoresis (Native-PAGE) 
To study different conformational states of the WT and mutant CHIP proteins, native gel
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electrophoresis was performed using NativePAGE
TM
 Bis-Tris Gels (12%) whereby the proteins 
get separated with maximum stability according to their molecular weight and electric charge. 
Wild type and mutant protein samples were prepared in 30 µl loading volume by adding 10 µg of 
MBP fusion protein to Native PAGE
TM
 sample buffer (4x), at a final concentration of 1x. To 
avoid protein denaturation, all the samples were prepared on ice. The lower (outer) buffer 




 Mini-Cell was filled with 300 ml of the 1x NativePAGE™ 
Anode Buffer previously prepared in 1000 ml volume by diluting 50 ml of the pre-chilled 
NativePAGE™ Running Buffer (20x) in deionized water. For the upper (outer) chamber, 200 ml 
of the Light Blue 1x NativePAGE™ Cathode Buffer was prepared in similar way using the 
NativePAGE™ Running Buffer (20x) and 1 ml of the NativePAGE™ Cathode Additive (20x). In 
order to provide easy visualization, protein samples were applied to the wells in the 
recommended maximum load volume prior to filling the inner chamber. Seven µl of the 
NativeMark™ Unstained Protein Standard was loaded as the marker reference for estimation of 
the size of the bands. Electrophoresis was performed at room temperature for 110 min applying a 
voltage of 150 V. The gel was further prepared for SimplyBlue SafeStain Coomassie staining as 
described in Section 3.16.1. 
 
3.16 Staining techniques 
*All the steps in the following staining methods were carried out at room temperature with slight 
agitation. 
 
3.16.1 Coomassie blue staining 
Following SDS-PAGE, the polyacrylamide gels were rinsed three times for 5 min with 150 ml 
MilliQ water. The gels were then incubated in 20 ml SimplyBlue
TM
 SafeStain solution (Thermo 
Fisher Scientific) for one hour. A clear gel background was achieved by an overnight washing 
with 150 ml MilliQ water before gel documentation and analysis.  
 
3.16.2 SYBRO Ruby staining 
The Molecular Probes SYBRO
®
 Ruby protein gel stain was used as an ultrasensitive luminescent 
stain to detect the proteins separated on the gels after SDS-PAGE. The gels were first placed into 
a clean container and fixed with 100 ml of fix solution (100 ml Methanol and 14 ml Acetic acid 
added to 86 ml MilliQ water) for 30 min. This step was repeated once more with fresh fix
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solution. Afterwards, the gels were stained with 60 ml of SYBRO
®
 Ruby gel stain (Thermo 
Fisher Scientific) and incubated overnight. In order to minimize the background staining, the gels 
were transferred to a clean container the next day and washed with 100 ml of wash solution (10 
ml Methanol and 7 ml Acetic acid added to 83 ml MilliQ water) for 30 min. The proteins were 




 XR System (BioRad 
Laboratories). Before imaging, the gels were washed twice for 5 min with ultrapure water to 
prevent possible corrosive damage to the imager. 
 
3.17 Immunoblot (western blot) analysis 
The SDS-PAGE-separated proteins were transferred on to a nitrocellulose membrane in order to 
be detected specifically by antibodies. The Nitrocellulose (NC) Membrane Filter Paper Sandwich 
(0.45 µm pore size, Novex, Life Technologies) was soaked together with the blotting pads and 
filter papers in 1x NuPAGE
®
 Transfer Buffer (Thermo Fisher Scientific), 10% Methanol, and 
0.1% Antioxidant and used to prepare a gel/membrane blotting sandwich following the supplier´s 
protocol (Invitrogen). The sandwich system was then placed vertically in a tank filled with 1x 
transfer buffer, where the proteins moved from the gel to the membrane at an electrical voltage of 
30 V, for one hour. The transferring process was cooled down using ice in the outer chamber of 
the tank. The presence of a protein ladder on the nitrocellulose membrane confirms a complete 
protein transfer step. Transferred proteins were further analyzed by antibody binding 
(immunoblotting) as described in the next two sections. 
 
3.17.1 Immunodetection 
The NC membrane was blocked for unspecific binding reactions by a one hour incubation in 10 
ml SuperBlock
TM 
(PBS) Blocking Buffer (Thermo Fisher Scientific) with 0.05% Tween 20 
(Sigma-Aldrich). The primary antibody (CHIP and Actin diluted 1:5000, HSC70 diluted 1:10000 
in blocking solution) was added to probe the membrane while shaking overnight at 4 °C. The 
next day the membrane was washed five times with 1x PBST containing 2 PBS tablets (Life 
Technologies) per 500 ml MilliQ water and 0.05% Tween 20, each time for 5 min and incubated 
in 10 ml blocking solution with 1:20000 diluted secondary antibody for one hour at room 
temperature. This was followed by a five-times washing step with 1x PBST before proceeding to 
protein detection step (see the section below).  
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3.17.2 Enhanced Chemo Luminescence (ECL) protein detection 
Finally, the membrane was developed and the immobilized proteins were visualized using the 
ECL detection method. In this method, the membrane was incubated for 5 min with an adequate 
volume of ECL solution to cover the membrane, which was prepared by mixing the enhancer and 
peroxide solutions 1:1, solutions being provided in the SuperSignal
®
 West Pico 
Chemoluminescent Substrate Kit (Thermo Scientific). The developed membrane was placed 




 XR System (FujiFilm, Tokyo, Japan) 
between two plastic foils with the protein side facing up, and analyzed by Image reader LAS 
1000 Pro v2.6 (Fujifilm) software. 
 
3.17.3 Stripping of membrane 
This technique was used to detect a different protein on the same nitrocellulose membrane. First, 
the membrane was washed with 10 ml PBS for 15 min. The previously bound antibodies were 
next stripped from the membrane by incubation in 10 ml of Restore
TM
 WesternBlot Stripping 
Buffer (Thermo Scientific) for 30 min. The membrane was then rinsed with PBS for another 15 
min before blocking and immunoblotting with a different set of antibodies (for the 








For in vitro recombinant protein studies 
 
4.1 Generation of mutant STUB1 constructs by site-directed mutagenesis 
Three mutations corresponding to p.K145Q (c.433A>C), p.M211I (c. 633G>A), and p.S236T (c. 
707G>C) were introduced into WT STUB1 cDNA in pETM-41-MBP/His vectors and the vectors 
were subsequently transformed into XL10-Gold Ultracompetent cells as described in Sections 3.1 
and 3.2. Bacterial colonies were selected and examined for successful transformation by PCR 
amplification and agarose gel electrophoresis (Figure 4.1.1 A). In order to confirm the presence 
of correct mutations, DNA sequencing was performed for those colonies with correct DNA size 
(1100 bp for STUB1+ MBP/His tag) using primers that cover the mutated region. The DNA 
sequence of each mutation is shown in Figure 4.1.1 B.  
A. 




Figure 4.1.1 Generation of STUB1 mutants by site-directed mutagenesis. The STUB1 cDNA pETM-
41-MBP/His vector was used for in vitro recombinant studies. A) Agarose gel showing the PCR product 
from individual bacterial colonies transformed with potential K145Q (lane 1, 2), M211I (lane 3, 4), and 
S236T (lane 5, 6) mutant cDNA plasmids using T7 promoter and T7 terminator primers. B) cDNA 
sequencing of mutant plasmids directly from bacterial colonies, confirming the introduction of K145Q, 
M211I and S236T mutations analyzed by FinchTV software.                                                 





All the mutant plasmids were purified from selected colonies (see Section 3.4) and DNA 
sequencing of the whole cDNA region verified that no additional mutations were present (data 
not shown) (for primer sequences and sequencing procedure, see Section 3.3). The plasmid 
vectors were used for further in vitro recombinant protein production together with E28K, N65S, 
T246M mutant vectors which had previously been prepared by other members of the research 
group [30]. 
 
4.2 Expression and purification of recombinant MBP-CHIP fusion proteins  
For in vitro studies of WT and mutant CHIP ligases, the His-tagged MBP fusion proteins were 
expressed and purified from BL21 competent E.coli following the Ni-NTA purification 
procedure as described in Section 3.5. Successful protein expression was verified for each mutant 
by SDS-PAGE and Coomassie blue staining before and after IPTG induction as shown in Figure 
4.2.1. The expressed MBP-CHIP proteins were seen as protein bands of ~72.5 kDa after 24 hours 
of IPTG induction. The fusion proteins were further cleaved by TEV protease in order to separate 
MBP from CHIP. To examine the optimal MBP/TEV ratio, three different ratios of TEV/MBP-
CHIP (1:10, 1:20, and 1:50, by mass) were tested during cleavage periods of one and two hours 
(see Section 3.6). Results from the SDS-PAGE analysis showed a complete cleavage after two 
hours with the ratio of TEV protease to MBP-CHIP 1:10 and 1:20, both generating three protein 
bands of MBP (~42.5 kDa), CHIP (~35 kDa), and TEV (~29 kDa) on the gel (Figure 4.2.2), with 
only a tiny fraction left of uncleaved MBP-CHIP. Therefore, a TEV/MBP-CHIP ratio of 1:10 for 
a 2 hour incubation was used for the downstream studies. 
                     
Figure 4.2.1 Expression of recombinant WT and mutant MBP-CHIP proteins. The expression of 
MBP-CHIP proteins of both WT and mutant forms at time 0 and 24 hours after induction of protein 







Figure 4.2.2 MBP-CHIP fusion protein 
cleavage by TEV protease. Coomassie blue 
stained SDS-PAGE gel loaded with 30 µg 
TEV-cleaved WT MBP-CHIP protein, using 
TEV protease to MBP-CHIP mass ratio of 1: 10 
and an incubation time of one hour (lane 1), 
1:10, two hours (lane 2), 1:20, one hour (lane 
3), 1:20, two hours (lane 4), 1:50, one hour 
(lane 5), and 1:50, two hours (lane 6). 
 
4.3 In vitro ubiquitination activity of E3 ubiquitin ligase CHIP for WT and 
mutant variants 
As a co-chaperone with ubiquitin ligase activity, CHIP participates in the ubiquitination of 
unfolded or misfolded substrates bound to chaperones via its U-box domain, mediating their 
degradation within the ubiquitin-proteasome pathway. In addition to the substrates, CHIP itself, 
and the heat shock protein chaperones are also known to be ubiquitinated by the same 
mechanism. In order to examine whether the enzymatic activity of CHIP is altered for the 
mutants, the ubiquitination assay was performed on recombinant WT and mutant CHIP both as 
MBP-fusion and MBP-free (cleaved) proteins. As described in Section 3.7, the reaction was 
performed for one hour at 37˚C, using Hsc70 recombinant protein as the ubiquitination substrate. 
The negative control sample was prepared without adding ubiquitin to the reaction. Proteins were 
then analyzed for both self- and Hsc70- ubiquitination by Western blotting against CHIP and 
Hsc70, respectively.  
Results are shown in Figure 4.3.1 A and B. A complete ubiquitination reaction was observed as 
additions of several 8.5 kDa ubiquitin molecules to Hsc70 protein (shown as protein bands with 
increasing molecular weight) for the WT and four of the CHIP mutants. However, N65S and 
T246M displayed impaired activity for both MBP-fusion and MBP-free forms (Figure 4.3.1, 
lanes 4 and 8). Hsc70 seemed to be mono-ubiquitinated by the N65S mutant, while no Hsc70-
ubiquitination was detected for the T246M. Furthermore, T246M was found to be non-functional 
in terms of self-ubiquitination for both MBP-fusion and cleaved proteins, but the N65S mutant 









Figure 4.3.1 Ubiquitination activity of recombinant WT and mutant CHIP proteins. In vitro 
ubiquitination activity assay was performed using WT (lane 2), E28K (lane 3), N65S (lane4), K145Q 
(lane5), M211I (lane 6), S236T (lane 7), and T246M (lane8) as ubiquitin ligases and Hsc70 recombinant 
protein as substrate. Self- ubiquitination and Hsc 70-ubiquitination activities were explored on MBP-
CHIP fusion proteins (A) and MBP- cleaved CHIP protein (B). The reaction was incubated for one hour 
at 37 °C, and samples were analyzed for both self- and Hsc70-ubiquitination by SDS-PAGE and Western 
blotting using antibodies against CHIP and Hsc70, respectively. As a negative control (lane1), the WT 
CHIP protein was used in a separate reaction set up without adding ubiquitin.  
In summary, the N65S and T246M variants were mostly affected by the mutation in this context, 
and the ubiquitination activity of proteins was not found to be significantly different when 
comparing cleaved (Figure 4.3.1 A) and MBP-tagged CHIP (Figure 4.3.1 B). 
 
4.4 Protein stability analysis by limited trypsin proteolysis 
As a serine protease, trypsin targets peptide chains at the carboxyl sides of the amino acids lysine 
or arginine. Some of these residues are normally buried inside the protein structure, being 
protected from proteolytic cleavage. The rate of tryptic cleavage can identify conformational 





in increased structural flexibility can accelerate trypsin access to cleavage sites, and thereby 
increase the degradation rate. Therefore, in order to elucidate the impaired ubiquitination activity 
observed in the N65S and T246M variants, and to further characterize the structure and dynamics 
of the mutants, limited proteolysis assay was performed using trypsin for digestion. MBP-cleaved 
CHIP proteins were subjected to trypsin cleavage during a time period of 30 min, and their 
susceptibility to proteolysis was analyzed at different time points by SDS-PAGE analysis and 





Figure 4.4.1 Limited proteolysis of WT and mutant CHIP proteins. The proteolytic susceptibility of 
MBP-free CHIP proteins was explored for WT and mutants using trypsin for protein digestion. A) 
Proteins were detected by SDS-PAGE and SYBRO Ruby staining after being subjected to proteolysis for 
various time periods (0-30 min). B) Full length proteins were quantified by Multi Gauge and ImageJ 
software, and the data for the average of three individual experiments were plotted against time. Each time 
point represents the mean of three readings ± SD (n=3). 
Results for the limited proteolysis of the WT and mutant CHIP proteins are presented in Figure 
4.4.1. Compared to the WT, increased rate of proteolysis was shown for all but one of the 
mutants as less detectable protein at time 5 min (and later), while N65S which was associated 
with a slower rate of trypsin cleavage. Among those mutants with increased susceptibility to 
proteolysis, the E28K and T246M variants were most affected, as indicated by a more rapid 
cleavage observed at 5 min for these mutants compared to other mutants including K145Q, 





Overall, the N65S was found to be the only mutant with increased structural stability against 
proteolysis. 
 
4.5 Small-scale CHIP protein purification by amylose resin 
 Amylose resin generates a cross-linked matrix with high affinity for maltose-binding protein 
which can be used for the isolation of proteins fused to MBP tag. In order to test whether the 
purification of CHIP, free from MBP, can be achieved with this system, the TEV-cleaved WT 
MBP-CHIP was bound to amylose resin (see Section 3.9). In this way, CHIP is expected to 
remain in the flow through while MBP should bind to the amylose resin. Figure 4.5.1 shows 
results from the SDS-PAGE and Coomassie blue staining of the flow through after two washing 
steps. The presence of MBP (~42.5 kDa) together with CHIP (~35 kDa) and TEV (~31 kDa) in 
both lanes indicates that MBP, unexpectedly, did not bind to the amylose resins and thus protein 
purification was unsuccessful. 
 
 
Figure 4.5.1 Purification of CHIP from MBP using amylose 
resin.  ~400 µg of the TEV-cleaved WT MBP-CHIP was subjected 
to amylose resin purification by being passed through a gravity flow 
column. The collected flow through from the first (lane 1) and 
second (lane 2) washing steps were analyzed by SDS-PAGE and 
Coomassie blue staining. 
4.6 Size-exclusion chromatography as a purification strategy 
Protein purification can be achieved by using gel-filtration chromatography columns in which the 
medium, consisting of a porous matrix of spherical particles, is packed to form a 
chromatographic bed. Upon the injection of protein solution, larger molecules pass through the 
column at the same speed as the buffer flows, and appear as the first elution peak on the 
chromatogram after being monitored for UV light absorption at 280 nm. Smaller molecules with 
partial access to the matrix pores elute from the column later in order of decreasing size and 
create the next peaks of the chromatogram. The smallest molecules with full access to the pores 





using different experimental conditions as described in Section 3.10. Fractions were collected and 
analyzed by SDS-PAGE and Coomassie blue staining. Following the procedure, three separated 
peaks were expected to be seen on the chromatogram due to the elution of dimeric CHIP (~70 
kDa), MBP (~42.5 kDa), and TEV protease (~28 kDa), in that order.  
Figure 4.6.1 shows the results from purification of 200 µg WT TEV-cleaved MBP-CHIP protein 
after passing through the Superdex 200 Increase 10/300 GL chromatography column, using 
phosphate buffer (20 mM NaH2PO4, pH 7.4) as the mobile phase. As is shown (Figure 4.6.1 A), 
the first small elution peak (Peak I, fractions 14, 15) appeared on the chromatogram at 
approximately 14 ml, immediately followed by another large peak (Peak II, fractions 16-20) at 16 
ml. The last peak (Peak III, fractions 28, 29) showed up at the end of the elution profile (21 ml) 





Figure 4.6.1 Separation of WT CHIP from MBP by size-exclusion chromatography. The experiment 
was performed on 200 µg TEV-cleaved WT MBP-CHIP at 0.5 ml/min with 50 ml phosphate buffer (pH 
7.4) as the mobile phase while monitoring protein absorbance at 280 nm. A) The elution profile obtained 
from chromatography on a Superdex 200 10/300 GL column at 4 °C, showing three elution peaks at 14, 





Results from SDS-PAGE analysis (Figure 4.6.1 B) indicated the presence of only CHIP (~35 
kDa) in fractions 14 and 15, corresponding to the first small peak. Fractions of peak II contained 
both CHIP and cleaved MBP (~42.5 kDa), and no protein band with molecular weight 
corresponding to TEV protease (28 kDa) was detected in fractions from the last peak. However, 
weak protein bands corresponding to CHIP seemed to be presented in these lanes. These results 
suggest that CHIP was eluted continuously in nearly all fractions, and a complete purification 
was not achieved during chromatography. Besides, those fractions containing only CHIP were 
too few to obtain a proper concentration of the protein. 
In the second attempt made to obtain pure CHIP protein (devoid of MBP), 2 mg of TEV-cleaved 
MBP-CHIP was subjected to gel-filtration chromatography, using a Superdex 200 Increase 





Figure 4.6.2 Separation of WT CHIP from MBP by size-exclusion chromatography. Two mg of 
TEV-cleaved WT MBP- CHIP was subjected to Superdex 200 10/300 GL chromatography column, 
flowing with the rate of 0.25 ml/min at 4 °C. A buffer containing 50 mM NaH2PO4, 5 mM DTT (pH 
7.2) was used as the mobile phase while monitoring protein absorbance at 280 nm. A) Elution profile 






Results showed three connected peaks at approximately 9 ml (Peak I, fractions 4, 5), 11 ml (Peak 
II, fractions 9, 10, 11), and 15 ml (Peak III, fractions 18, 19, 20) (Figure 4.6.2 A). SDS-PAGE 
analysis of protein fractions detected CHIP and MBP as the major protein contents of the first 
two peaks and the last one, respectively (Figure 4.6.2 B). But all fractions seemed to contain 
other proteins, too. In fact, proteins were separated with a higher yield in this experiment than the 
previous one and the percentage of MBP was minor compared to the total yield of purified CHIP. 
However, the required concentration of CHIP was not yet achieved. 
Using a longer chromatography column (Superdex 75 Increase 10/300 GL), the gel-filtration 
analysis was repeated once again for 2 mg of the cleaved WT MBP-CHIP. Columns with a longer 
packed bed provide more resolving power, and improve resolution in general. The column was 





Figure 4.6.3 Separation of WT CHIP from MBP fusion protein by size-exclusion chromatography. 
Purification of 2 mg MBP-cleaved WT CHIP was tested on Superdex 75 10/300 GL column at 0.5 
ml/min at 4 °C. A buffer containing 100 mM Hepes (pH 8), 5 mM DTT, and 100 mM NaCl was 
used as the mobile phase while monitoring protein absorbance at 280 nm. A) Elution profile showing 






Results from the protein elution profile (Figure 4.6.3 A) suggested an improved separation as can 
be seen by the appearance of two partially separated peaks at 9 ml (Peak I, fractions 12, 13) and 
11 ml (Peak II, fraction 16) associated with CHIP and MBP proteins, respectively. This was 
followed by another peak at 19 ml (Peak III, fraction 25). SDS-PAGE analysis results (Figure 
4.6.3 B) showed an increased amount of purified CHIP in fractions 12 and 13. However, the 
percentage of total MBP and TEV protease detected in these fractions was still substantial (~41% 
in fraction 12 and ~57% in fraction 13). No protein band was observed in fraction 25, 
corresponding to the last peak, probably because the amount of protein was too low to be 
detected by Coomassie staining.  
Since a complete separation of CHIP from MBP could not be achieved neither with amylose resin 
nor with size-exclusion chromatography methods, it was decided that the remaining experiments 
for the In vitro protein studies should be performed on the MBP fusion proteins.          
                                    
4.7 Oligomeric structure of the WT and mutant recombinant MBP-CHIP 
fusion proteins  
As mentioned earlier, CHIP proteins are functional as dimers that are formed through interactions 
between their putative coiled-coil domains [36, 37]. To study the effects of mutations on 
oligomerization properties of CHIP protein, gel-filtration analysis was performed on recombinant 
MBP-CHIP fusion protein of both WT and mutant forms as described in Section 3.11. With this 
method, different conformational states of protein, including monomeric, dimeric, and oligomeric 
forms, can be separated according to molecular weight by passage through the size-exclusion 
chromatography column. Results from gel-filtration chromatography of WT MBP-CHIP 
indicated the presence of dimeric structures as the dominant oligomeric state of the protein, 
visible as a high peak located at approximately 12 ml (Figure 4.7.1 A, Peak II) on the 
chromatogram. The amount of other protein structures appeared to be less as can be seen by the 
smaller oligomeric and monomeric peaks at ~9 ml (Peak I) and ~15 ml (Peak III), respectively. 
SDS-PAGE analysis confirmed the presence of MBP-CHIP fusion proteins with protein bands of 
~77.5 kDa in all fractions (Figure 4.7.1 B). SDS-PAGE though is not suitable for studying 







B.   
 
    
Figure 4.7.1 Size-exclusion chromatography of WT MBP-CHIP fusion protein. One mg of WT 
MBP fusion protein was subjected to size-exclusion chromatography on superdex 200 10/100 GL 
column at 0.3 ml/min at 4 °C. ~50 ml of phosphate buffer (20 mM NaH2PO4, pH 7.4) was used as the 
mobile phase while monitoring protein absorbance at 280 nm. A) Elution profile showing three peaks at 
9, 12, and 15 ml. B) SDS-PAGE analysis of collected fractions showing the presence of MBP-CHIP 
fusion protein in Peak I (fractions 5, 6), II (fractions 10-12), and III (fractions 18, 19). 
The process was repeated for all the mutants under the same experimental conditions. Figure 
4.7.2 displays the elution profiles of mutant proteins as well as results from the SDS-PAGE 




























     
Figure 4.7.2 Size-exclusion chromatography of mutant recombinant MBP-CHIP fusion proteins. 
All the experiments were performed on one mg of MBP-CHIP at 0.3 ml/min at 4 °C, using Superdex 200 
10/100 GL columns and ~50 ml of phosphate buffer (20 mM NaH2PO4, pH 7.4) as the mobile phase 
while monitoring protein absorbance at 280 nm. The elution profile and SDS-PAGE analysis of fractions 
corresponding to Peaks I-IV are shown for mutants E28K (A, B), N65S (C, D), K145Q (E, F), M211I 
(G, H), S236T (I, J), and T246M (K, L). 
As shown for all the mutants, except for T246M, the oligomer and dimer peaks seemed to be 
connected with another peak at ~10 ml, which was speculated to be associated with trimeric 
structures (Figure 4.7.2 A, C, E, G, I, Peak II). The presence of MBP-CHIP fusion protein was 









addition, small amounts of cleaved MBP protein and one additional purified protein of ~55 kDa 
(marked with*) were detected together in fractions corresponding to the monomer peaks of 
E28K, N65S, and T246M mutants (Figure 4.7.2 B, D, L, Peak IV). 
In the chromatogram of E28K, a smaller peak appeared at ~12 ml compared to what was seen for 
WT (Figure 4.7.2 A, Peak III, with UV absorbance of 0.07 nm vs. 0.16 nm), indicating the 
existence of a lower amount of dimeric structures for this mutant. In addition, trimeric structures 
seemed to be present at approximately the same level as the dimers as evidenced by a peak with 
UV absorbance of 0.06 nm, located at ~10 ml (Peak II). In contrast, for the N65S mutant, the 
dimer peak was higher compared to the WT (Figure 4.7.2 C, Peak III, UV absorbance of 0.23 nm 
vs. 0.16 nm). Results for K145Q, M211I, and S236T were similar to the WT (Figure 4.7.2 E-J). 
The K145Q mutant presented with a small oligomer peak at ~8 ml (Figure 4.7.2 E, Peak I). 
Moreover, the dimer peak was slightly smaller in this mutant as well as S236T compared to the 
WT (compare Peak III in Figure 4.7.1 A and 4.7.2 E, I). The presence of MBP-CHIP was not 
confirmed in the oligomer peaks of K145Q, M211I, and S236T as well as the monomer peak of 
S236T by SDS-PAGE and Coomassie blue staining (Figure 4.7.2 F, H, J, fractions corresponding 
to Peak I and IV) probably due to the small amount of protein. Finally, the T246M mutant was 
characterized by a remarkably increased amount of oligomeric structures, shown by a high 
oligomer peak at ~8 ml with UV absorbance of approximately 0.1 nm (Figure 4.7.2 K, Peak I,). 
This was continued by a very small dimer peak at ~11 ml (Peak II) and further by two connected 
peaks at ~13.5 ml (Peak III) and ~14.5 ml (Peak IV) in which small amounts of unidentified 
protein with ~55 kDa molecular weight and cleaved MBP were identified by SDS-PAGE analysis 
(Figure 4.7.2 L, fractions 16-19). 
Altogether, these data suggested that the conformational structure of MBP-CHIP fusion protein is 
most prominently affected by mutations E28K and T246M, demonstrated by elevated trimer and 
oligomer peaks on their chromatograms. Moreover, N65S was identified to contain large amounts 
of dimeric structures, which was shown by a dimer peak higher than that of WT. Lastly, K145Q, 
M211I, and S236T displayed chromatographic patterns similar to the WT with only minor 





4.8 Oligomeric states of MBP-CHIP fusion proteins analyzed using native 
electrophoresis (native-PAGE) 
Native polyacrylamide gel electrophoresis allows for a high-resolution analysis of the oligomeric 
state and molecular mass of native protein structure. This technique uses Coomassie G-250 as a 
charge-shift molecule which provides a net negative charge, and directs the electrophoretic 
mobility of proteins towards the anode while maintaining the proteins in their native 
conformation. The migration of 10 µg wild type and mutant MBP-CHIP proteins were 
determined on a native-PAGE gel as described in Section 3.15.3. Results are shown in Figure 
4.8.1. The different migration patterns of CHIP protein band size (compared to 35 kDa observed 
in SDS-PAGE) is due to the fact that the mobility of proteins on a BN gel is influenced by both 
charge and size. Therefore, the molecular weight of proteins cannot be estimated with this 
method. Separation of five major protein bands in the size range of > 242 to >1048 kDa was 
observed for all the samples apart from T246M (Figure 4.8.1, lane 7) in which a higher-order 
oligomer band (≥1048 kDa) was the only visualized band, suggesting the formation of aggregates 
for this mutant. 
                        
Figure 4.8.1 Oligomeric states of the WT and mutant MBP-CHIP by native gel electrophoresis. 
Ten µg of each WT (lane 1), E28K (lane 2), N65S (lane 3), K145Q (lane 4), M211I (lane 5), S236T 
(lane 6), and T246M (lane 7) MBP fusion protein was tested for migration on a 12% native-PAGE gel. 
Protein bands were visualized following Coomassie blue staining.  
The E28K mutant (lane 2) showed lower amounts of monomers, as indicated by a faint band at 
~242 kDa on the gel. In addition, the signal for dimers seemed to be slightly weaker for this 





order oligomers (720-1048 kDa) in the dimer-oligomer equilibrium of the protein. Overall, these 
results suggested that while the higher-order oligomers serve as the major conformational state of 
the T246M, other mutants displayed almost the same oligomeric patterns as the WT with small 
deviations observed for the E28K variant. 
 
4.9 Secondary structures of WT and mutant MBP-CHIP fusion proteins 
measured by CD 
Circular dichroism (CD) refers to the differential absorption of the left-handed and right-handed 
circularly polarized components of the plane polarized light, after passing through the subject. 
The CD spectrum is obtained when the dichroism is measured as a function of wavelength. For a 
protein sample, absorption in the far-UV region (180-250 nm) is related to the peptide bond. 
Therefore, different secondary structure composition of proteins leads to characteristic CD 
spectra in this region. Results from the far-UV CD spectra of both WT and mutant MBP fusion 
proteins showed two minima at 208 and 222 nm, which is typical of proteins with a high helical 
content (Figure 4.9.1) [68]. Different extents of CD signals ([Ɵ]) observed for the mutants 
indicate changes of the conformational properties of these proteins relative to WT. 
 
 
Figure 4.9.1 Far-UV CD spectra of WT 
and mutant MBP-CHIP proteins. CD 
spectra for WT (dark blue), E28K (red), 
N65S (green), K145Q (dark purple), M211I 
(light blue), S236T (orange), and T246M 
(light purple) are shown in units of molar 
ellipticity versus wavelength (nm). Protein 
samples were used at 6 µM concentration in a 
buffer containing 10 mM KH2PO4 (pH 7.4) 
and 100 mM NaF. The spectra were recorded 
in the range of 185-260 nm at 20 °C. The 
spectra shown were the average of four 
separate scans. Buffer scans were subtracted 
from the protein spectra, using the Spectra 






In order to provide an estimation of the secondary structure composition of WT and mutant CHIP 
proteins, the spectra corresponding to the CHIP portion were generated by subtraction of an 
“MBP-only” spectrum from the spectra of the MBP-CHIP fusion proteins as is shown for WT in 
Figure 4.9.2 A. The resulted CD spectra were further analyzed using CONTIN algorithm 
(Dichroweb software) [69, 70]. The distributions of α-helix and β-sheet are illustrated for each 
sample in Figure 4.9.2 B. Wild type protein was estimated to contain ~24% α-helices and ~10% 
β-sheet structures after being subtracted from MBP portion. Decreased percentages of α-helix 
(~22-23%) were calculated for those mutants locating at similar levels of ellipticity, but lower 
than the WT (E28K, K145Q, M211I, and S236T, Figure 4.9.1), and the largest loss of α-helicity 
(~11%) was observed for T246M mutant (Figure 4.9.1, light purple line). On the opposite side, 
N65S with ~30% α-helix and ~8% β-sheet content was identified as the only mutant with 
increased α-helical content compared to the WT (Figure 4.9.1, green line). Decreased α-helicity 




Figure 4.9.2 Secondary structure content calculation of WT and mutant CHIPs. Each of the WT 
and mutant CHIP spectra were subtracted from an ‘MBP only’ spectrum, and further analyzed for 
secondary structure content. A) Representative CD spectra for MBP-CHIP/ WT (blue), MBP (green) and 
the calculated WT CHIP (yellow) are shown. The WT CHIP spectrum was obtained by subtraction of 
the MBP spectrum from the MBP-CHIP/WT spectrum. B) Quantitative analysis of α-helix (blue) and β-
sheet (red) percentage of WT and mutant CHIPs, performed on MBP-subtracted spectra by using 






4.10 Conformational changes in CHIP structure as a function of temperature 
The effects of mutations on the thermal stability of the CHIP protein were next examined through 
the investigation of changes in the molar ellipticity ([Ɵ]) of the WT and mutant MBP-CHIP 
fusion proteins over a temperature range of 20-90 °C, at 222 nm (Figure 4.10.1). The mid-point 
of the transitions (Tm) for denaturation of each sample is given in Table 4.10.1. Three transition 
temperatures in the range of ~41-45 °C, ~55-57 °C, and ~62-74 °C were monitored for 
denaturation of all protein samples excluding T246M which was appeared with two (Tm)s of 55.4 
°C for the first transition and 66.8 °C for the second transition (Figure 4.10.1, light purple line 
and Table 4.10.1).  
      
 
Figure 4.10.1 Thermal 
denaturation profiles of WT and 
mutant MBP-CHIP proteins. 
Thermal unfolding curves were 
obtained for WT (dark blue), E28K 
(red), N65S (green), K145Q (dark 
purple), M211I (light blue), S236T 
(orange), and T246M (light purple) 
by monitoring CD signal at 222 nm 
from 20 to 90 °C. Each curve was 
smoothed and analyzed for 
denaturation transitions by Spectra 
manager software. The curves are 
plotted in units of molar ellipticity 
versus temperature. 
Table 4.10.1 Mid-point of transitions for thermal unfolding of MBP-CHIP proteins. Values are 
given by Spectra manager software in °C. 
 WT E28K N65S K145Q M211I S236T T246M 
Tm (1) 44.2 42.4 44.5 42.7 43.9 41.2 - 
Tm (2) 55.8 55 56.2 57 56.2 56.2 55.4 
Tm (3) 64.5 62.4 65.1 69.5 67.7 73.8 66.8 
 
T246M was also shown as the only mutant with a broad, non-co-operative unfolding pattern, 





pathways similar to the WT and with more apparent transitions than that of T246M, which may 
point to loss of intermediate structures during their thermal denaturation [71]. 
In addition to the MBP-CHIP fusion proteins, the thermal denaturation of MBP protein itself was 
investigated by CD spectroscopy. As shown in Figure 4.10.2, a Tm of 56 °C was identified as the 
only unfolding transition for this protein, which nearly coincides with the second transition of 
MBP-fusion protein samples (compare with Table 4.10.1, Tm (2), small deviations (±1 °C) might 
be due to the binding of CHIP to MBP). Therefore, it is most likely that the first and third 
transitions on the thermal denaturation curves of MBP-CHIP proteins are associated with 
unfolding of CHIP protein itself (not MBP). It was further speculated that the first transition 
represents denaturation of the dimeric CHIP, while the third transition represents unfolding of the 
monomeric CHIP (see Section 5.2.4). 
 
 
Figure 4.10.2 Thermal denaturation profile for 
MBP. CD signal was monitored at 222 nm for 6 µM 
of MBP in a buffer containing 10 mM KH2PO4 (pH 
7.4) and 100 mM NaF over a temperature range of 
20 to 90 °C with nitrogen flow rate of 5 l/min. 
Spectra manager software was used for smoothing 
the obtained curve as well as calculation of unfolding 
transition. 
 
Considering the Tm of 44.2 °C as the dimeric unfolding transition of the WT CHIP, all of the 
mutants showed Tm values smaller than that of the WT (Table 4.10.1, Tm(1)), indicating decreased 
thermal stability of dimeric structures for these proteins. Hence, S236T with the dimeric Tm of 
41.2 °C was regarded as the least stabilized protein in dimeric conformation (Figure 4.10.1, 
orange line and Table 4.10.1). Moreover, the absence of first transition on the thermal 
denaturation curve of T246M (light purple line) suggested a very small amount of dimeric 





Thermal unfolding of mutant CHIP proteins seemed to occur more differently in monomeric 
phase than the dimeric phase, as can be seen by the melting transitions at a broader temperature 
range of ~62-74 °C than that of the dimeric transitions (Table 4.10.1, Tm(1) vs. Tm(3)). Compared 
to the WT with monomeric unfolding transition of 64.5 °C, E28K showed transition at lower 
temperature (62.4 °C), indicating a less conformational stability in monomeric state for this 
mutant. However, other mutants acquired more stabilize monomeric structures, displayed by Tm 
values larger than 64.5 °C. In this regard, S236T with Tm of 73.8 °C was presented as the protein 
with the highest thermal stability, followed sequentially by K145Q, M211I, T246M, and N65S.  
  
For in cellulo protein studies 
 
4.11 Generation of mutant STUB1 constructs by site-directed mutagenesis 
Mutations including p.K145Q (c.433A>C), p.M211I (c. 633G>A), and p.S236T (c. 707G>C) 
were introduced into WT STUB1 cDNA in pcDNA3.1-V5/HisB plasmids, as described in Section 





Figure 4.11.1 Generation of STUB1 mutants by site-directed mutagenesis. The STUB1 cDNA 
pcDNA 3.1-V5/HisB vector was used for in cellulo protein studies. A) Agarose gel showing the PCR 
amplification product from individual bacterial colonies transformed with potential K145Q (lane 1, 2), 
M211I (lane 3, 4), and S236T (lane 5, 6) mutant cDNA plasmids using T7 promoter and T7 terminator 
primers. B) cDNA sequencing of mutant plasmids directly from bacterial colonies, confirming the 






Successfully transformed colonies were selected and verified by PCR amplification and agarose 
gel electrophoresis (Figure 4.11.1 A). DNA sequencing was further performed on selected 
colonies in order to confirm the introduced mutations (Figure 4.11.1, B). Plasmids were purified, 
and verified for correct mutations once again with DNA sequencing of the whole STUB1 cDNA 
insert (data not shown). Vectors containing E28K, N65S, and T246M mutations were prepared 
during previous studies performed by the group. 
 
4.12 Effects of mutations on the exogenous CHIP protein expression level in 
HEK293 cells 
To investigate whether the expression level of exogenous CHIP protein was changed for the 
different mutant proteins, HEK293 cells were transiently transfected with the WT and mutant 
STUB1 pcDNA3.1-V5/HisB plasmids. A pcDNA vector lacking the STUB1 cDNA insert was 
used as a negative control. Cell lysates were analyzed by SDS-PAGE and immunoblotting using 
CHIP specific antibody. Equal amounts of proteins were loaded on the gel and actin bands were 
used for normalization during quantification. Results for the Western blotting analysis and 
protein expression levels are shown in Figure 4.12.1. The protein band corresponding to CHIP-
V5/N65S (Figure 4.12.1 A, lane 4) migrates slightly faster on SDS-PAGE in comparison to the 
WT and other mutants probably because of protein conformational changes induced by this 
mutation. 
The exogenous CHIP-V5 and endogenous CHIP proteins were identified at ~37 and ~35 kDa, 
respectively. Another band at the molecular weight of ~32 kDa was also detected on the 
membrane for all the proteins but not the negative control (Figure 4.12.1 A, marked with *), 
which might be due to the degradation of exogenous CHIP in cells. When normalized with actin, 
four mutants including E28K, N65S, K145Q, and M211I showed higher expression levels than 
the WT protein (Figure 4.12.1 A, lanes 3-6 and Figure 4.12.1 B). Among them, E28K with a 
relative protein level of ~122% had the most increased level of expression sequentially followed 
by K145Q, N65S, and M211I. 
On the contrary, the two mutants S236T and T246M were found to be less expressed compared to 
the WT, shown by the protein levels of ~44% and ~87%, correspondingly. Taken together, these 





cellulo, by either an increase or decrease in expression level compared to WT. However, further 





Figure 4.12.1 Expression of WT and mutant CHIP proteins in transiently transfected HEK293 
cells. 10 µg of total lysate were analyzed for the level of exogenous CHIP-V5 protein expression after 
being transfected by the WT and mutant CHIP pcDNA 3.1-V5/HisB vectors. A) SDS-PAGE and 
immunoblotting analysis of cell lysates corresponding to empty vector (lane 1), WT (lane 2), E28K (lane 
3), N65S (lane 4), K145Q (lane 5), M211I (lane 6), S236T (lane 7), and T246M (lane 8), using anti-
CHIP antibody. Actin was used as an internal loading control. B) The level of CHIP-V5 proteins 







Ataxia is a heterogeneous group of neurological disorders that involves degeneration or abnormal 
development of the cerebellum and spinal cord [51, 53]. Patients with ataxia are mainly 
characterized by walking, speech, and vision difficulties due to loss of coordination during 
muscle movements. Environmental factors as well as underlying medical conditions such as 
stroke, infection, or vitamin deficiencies are responsible for the acquired ataxia. Many ataxias, 
however, develop as genetic diseases with dominant, recessive, X-linked, or mitochondrial modes 
of inheritance. Inherited ataxias are estimated to include over 50 causative genes, and occur with 
a prevalence of 1-9 per 100,000 people [72]. 
Early attempts to discover the genetic origin of ataxia diseases were made in 1993 while CAG 
repeat expansions were identified as the common causative mechanism for many dominantly 
inherited ataxias including spinocerebellar ataxias (SCAs) [73]. Later, with the development of 
next-generation technology, several new genes were found to cause ataxia, including ATP2B3, 
KCND3, DNMT1, and TPP1 [74, 75]. Improved understanding of ataxia genes has led to 
identification of more disease pathways. For instance, many ataxia genes are involved in the 
ubiquitin-proteasome pathway. Mutations in the components of this pathway cause the 
accumulation of misfolded and damaged proteins inside the cell which, consequently, result in 
toxicity and cell death. An example is E3 ubiquitin ligase RNF170 which is found to be mutated 
in sensory ataxia. Another E3 ligase, parkin, interacts with deubiquitinating enzyme Ataxin-3. 
Mutated ataxin-3 results in more deubiquitinated parkin that accumulates and causes 
development of Parkinson disease (PD). Recently, mutations in the STUB1 gene encoding CHIP 
E3 ligase have been found to be associated with ARCA and hypogonadism [72]. 
In the present study, six different STUB1 mutations including E28K, N65S, K145Q, M211I, 
S236T, and T246M were characterized in terms of (1) ubiquitination activity, (2) 
structural/conformational properties, and (3) exogenous expression of the encoded CHIP protein 
using in vitro/in cellulo methods. These mutations were identified and reported by exome 
sequencing studies on individual families with SCAR 16 disease [30, 49, 57-63]. Some, including 
E28K, N65S, and T246M have been described previously [30, 61]. The selection of the three 





 protein structure by PyMol software, since the amino acid substitutions seem to be situated in 
crucial regions for CHIP dimerization or protein-protein interactions. 
 
5.1 The effects of different STUB1 mutations on the E3 ubiquitin ligase activity 
of CHIP  
The in vitro ubiquitination activity assay showed reduced levels of Hsc70-ubiquitination activity 
for CHIP-N65S (Figure 4.3.1). This mutation is located in the TPR domain affecting a residue 
that was previously reported to be involved in CHIP substrate binding [76]. Considering the 
intact auto-ubiquitination activity of the N65S mutant, the mutation is therefore predicted to 
impact CHIP substrate binding affinity and reduces its ability to ubiquitinate Hsc70. Another 
mutation in the same domain (E28K) resulted in a similar ubiquitination activity as the WT for 
both Hsc70 substrate and itself (auto-ubiquitination), indicating that the substrate binding of 
CHIP was not affected by this mutation. These assumptions were further supported by the 
microscale thermophoresis (MST) analysis of the E28K and N65S mutants which was performed 
during MST demo day by using a Monolith NT.115 instrument (see Appendix 7.2). In this 
method, the biomolecular interactions can be measured precisely and within a short time by 
detecting changes in the hydrogen shell, charge or size of molecules while passing through 
microscopic temperature gradients [77, 78]. MST analysis of CHIP vs Hsp70 displayed no 
interaction for N65S, while a strong interaction (with a Kd of 9 nM) was observed for E28K. In 
addition, a study by Heimdal et al. on ubiquitination activity levels of N65S and E28K variants 
showed similar results for both Hsc70- and self-ubiquitination. However, the co-
immunoprecipitation assays failed to firmly demonstrate the impaired binding between N65S and 
Hsc70 [30].  
A complete loss of ubiquitination activity was observed for CHIP-T246M for both Hsc70 
substrate and CHIP itself, indicating the deleterious effect of this mutation on CHIP’s ubiquitin 
ligase activity. In fact, the T246M substitution (located at the U-box domain of CHIP) can affect 
its interactions with the ubiquitin-proteasome pathway compartments and result in abolished 
ubiquitination activity of the protein. This idea was also suggested by Shi et al., who discovered 
the T246M mutation and tested its ubiquitination activity as well as interactions with Hsp70 





interaction between T246M and Hsp70 compared to the WT. However, CHIP-T246M was not 
able to ubiquitinate Hsp70 as well as itself. Thus, the lack of chaperone activity for this mutant 
was suggested to be due to a defect in the U-box domain rather than the inability to bind to 
chaperone substrate. 
Reduced substrate affinity of CHIP-N65S and the loss of function of CHIP-T246M are assumed 
to contribute to the development of ARCA disease through accumulation of misfolded client 
proteins and increased potential for toxic aggregation in cells of homozygous patients carrying 
these mutations. Patients affected by the T246M mutation are reported to develop hypogonadism 
together with ataxia (Gordon Holmes Syndrome) which was not found in cases carrying the other 
STUB1 mutations [61]. Further studies are required to demonstrate whether the location of the 
mutation is critical for the development of hypogonadism. 
Results from the ubiquitination activity of K145Q, M211I, and S236T mutants revealed similar 
levels of function as compared to the WT. Other studies reporting the activity of these mutations 
were few, and limited to bioinformatics predictions [58, 60, 62]. These three mutations together 
with E28K exist as compound heterozygous with either a non-sense or deletion mutation in the 
genome of related ARCA patients [30, 58, 60, 62]. Therefore, the development of ARCA in these 
families is likely to be more related to the effect of second alleles [30]. 
 
5.2 Structural and conformational characterization of WT and mutant CHIP 
proteins 
 
5.2.1 Oligomerization studies discovered high aggregation propensity for CHIP-T246M 
Size-exclusion chromatography of MBP-CHIP proteins displayed a high oligomeric peak on the 
elution profile of the mutant T246M which did not appear for the WT and the rest of the mutants, 
pointing to a conformational change in the structure of this mutant that leads to an induced 
tendency to form aggregates (Figure 4.7.2 K, L). A study on the native CHIP homologues from 
Homo sapiens (hCHIP) and D.melanogaster (dCHIP) indicated the necessity of dimerization for 
activity of hCHIP by performing ubiquitination assays on full-length hCHIP as well as deletion 
mutants lacking the putative coiled-coil domain [36]. Another study analyzing the crystal 





RING-finger families of E3 ubiquitin ligases, which play essential roles in the stability and 
functionality of these enzymes [79]. Therefore, the complete loss of function observed in the in 
vitro ubiquitination activity assay for the CHIP-T246M mutant might be caused by both impaired 
ubiquitin ligase activity (as a result of impaired interaction with ubiquitination enzymes) and 
formation of oligomeric protein structures. In addition to T246M, E28K presented higher 
trimeric/tetrameric structures compared to the WT and other mutants (Figure 4.7.2 A, B). The 
level of structural modifications imposed by the mutation, however, might not be sufficiently 
severe to affect the in vitro ubiquitination activity as this appeared to be similar to that of the WT. 
Moreover, increased amount of dimeric structures were noticed for N65S through observation of 
a dimer peak higher than that of the WT (Figure 4.7.2 C, D). However, since the mutation is not 
located in the coiled-coil domain of CHIP, this finding cannot be considered as a direct effect of 
the location of mutation on protein dimerization. 
These findings are in agreement with native gel electrophoresis results; a higher-order oligomer 
band was detected for T246M, indicating the formation of aggregates for this mutant, and a small 
shift towards the lower-order oligomeric structures (trimer/tetramer bands) was discovered for 
E28K (Figure 4.8.1). Small oligomerization changes occuring in the structure of N65S (and other 
CHIP mutants) were detected by gel-filtration analysis, while native-PAGE methodology was not 
able to show these changes possibly due to a lower resolution of this method per se. Native-
PAGE is generally considered a reliable method for determination of the oligomeric states of 
proteins, but, special conditions applied to this technique such as the bound Coomassie blue dye 
can affect the folding of the proteins, and lead to a small decrease in the accuracy of the method 
[80]. Nevertheless, the rapidity and relative simplicity of this approach allows for its general use 
in the investigation of molecular mass and oligomeric states of proteins. Several studies have 
reported the analysis of membrane protein complexes [81, 82] as well as neurodegeneration-
linked protein aggregates such as parkin and α-synuclein by using this technique [83, 84]. 
It is important to mention that these observations could be influenced by the presence of MBP 
attached to CHIP during the experiments. But, due to similar conditions applied to all 
chromatography procedures, the effect of MBP on CHIP oligomerization properties is considered 






5.2.2 Mutants T246M and N65S displayed remarkable differences in terms of secondary 
structure content  
Crystallographic analysis of mammalian (mouse) CHIP indicates a high degree of α-helicity in 
the structure of this protein due to the presence of two domains consisting mainly of α-helices 
(TPR and coiled-coiled domains) [37]. Our far-UV spectroscopy data of the wild type CHIP 
displayed an α-helical content that corresponds well with the crystallography data (Figure 4.9.1). 
Reduced levels of elipticity were, however, observed in the spectra of the majority of mutants, 
suggesting a decreased level of α-helical structure content of these proteins compared to the WT. 
The largest loss of α-helicity was shown by the T246M mutant (by ~13%) with the mutation 
located in the second β hairpin of the U-box domain. Given the fact that methionine (the amino 
acid for which threonine is exchanged in the T246M mutation) has a high helix-forming 
propensity [85], it is not clear why this mutation results in such a substantial decrease in α-
helicity. Nevertheless, it might be possible that the substitution of threonine as a polar amino acid 
by methionine as a non-polar amino acid disrupts the overall non-covalent polar interactions, 
from which the stabilizing energy of a fold comes from, and therefore causes some reductions in 
the level of α-helical structure content of the protein [86]. The loss of α-helix structures was 
associated with increased percentage of β-sheet in all cases. Mutants with increased β-sheet 
content have been proposed to show increased propensity for protein aggregation as a 
consequence of having exposed or extended β-sheet edges which are normally buried inside their 
native structure [71]. Accordingly, the aggregation behavior discovered by oligomerization 
studies of CHIP-T246M can be related to the significant increase in β-sheet content of this 
mutant (by ~20%). Additional studies on the structure and interactions of T246M are required to 
support this notion.   
On the contrary, being located at the beginning of three antiparallel α-helices in the TPR domain 
of CHIP, the N65S mutation generated a protein structure with considerably increased secondary 
structure content of α-helices (by ~7%). However, this observation does not correlate with the 
‘helix breaker’ role of serine as the exchanged amino acid in this mutation [87]. N65S was also 
identified with a larger amount of dimeric structures during gel-filtration analysis. But the 
relationship between increased α-helicity and dimerization still remains to be understood. 





during data analysis (Figure 4.9.2), it is important to consider limitations associated with the use 
of MBP fusion proteins while monitoring structural characteristics. The overall protein folding 
and assembly may be different for MBP-CHIP fusion proteins compared to purified CHIP. In 
addition, mutations causing misfolding and aggregation (T246M, for example) may have a less 
severe effect in the presence of MBP as a protein with solubilizing activity [71]. In spite of these 
issues, two studies have reported the secondary structure of purified CHIP with a similar high 
degree of α-helicity as was found in this study [36, 41]. In addition, regarding the fact that these 
experiments were performed under the same conditions with the aim of comparing WT and 
mutant proteins, the findings are believed to be useful and scientifically reliable.  
5.2.3 CHIP-N65S: the only mutant with increased structural stability against limited 
proteolysis 
Limited proteolysis provides a general method to unravel molecular features as well as structure-
function relationships of many proteins. Numerous studies have successfully uncovered protein 
folding pathways [88, 89] and identified optimal folding conditions for novel proteins [90-92] by 
using this approach. Protein conformational features predicted by limited proteolysis often 
correlate with results from other biophysical and spectroscopic methods such as circular 
dichroism and nuclear magnetic resonance (NMR) spectroscopy [93].  
The sites of proteolysis across a protein surface are very few and restricted to areas characterized 
by enhanced backbone flexibility (segmental mobility). Therefore limited proteolysis of a 
globular protein occurs mostly at flexible loops, and regular secondary structures (such as 
helices) are not subjected to cleavage [93]. Studies on the proteolysis of a variety of proteins with 
known 3D structures supported this idea, indicating that cleavage mainly occurs at the site of 
loops, but never at α-helices [92, 94].  
Taking this information into account, decreased susceptibility identified for CHIP-N65S against 
limited proteolysis is expected to be associated with a structure that contains a larger number of 
α-helices (compared to the WT) which is confirmed by far-UV CD spectra of the mutant (Figure 
4.4.1 and 4.9.1). The induced stability and proteolytic resistance in the structure of N65S may 
also be the consequence of more dimeric states discovered during gel-filtration analysis of this 
protein. However, more investigation is required in order to clarify the relationship between these 





Limited proteolysis monitors the process of protein aggregation via the presence of cross-β 
structures which are resistant to proteolytic degradation. However, the unfolded and (or) flexible 
states of protein made in the early stages of aggregation cause an enhanced susceptibility to 
proteolysis [93]. Considering the high levels of oligomerization observed during size-exclusion 
chromatography of CHIP-T246M, the initial formation of protein aggregates is suggested to 
make this mutant more susceptible than the other variants towards limited proteolysis.  
Mutants including K145Q, M211I, and S236T displayed approximately the same extent of 
susceptibility towards proteolysis, being lower than that of T246M but still higher compared to 
the WT. These proteins are suggested to achieve some loose, flexible structures which make them 
more sensitive towards proteolytic cleavage. Likewise, results from far-UV spectroscopy of these 
mutants (together with E28K) showed similar levels of ellipticity, but lower than the WT 
spectrum, indicating that these mutants have lost the same amount of α-helical secondary 
structure. Therefore, a decreased number of α-helices in the structure of K145Q, M211I, and 
S236T mutants could be the reason behind their reduced stability against limited proteolysis. In 
contrast, CHIP-E28K presented approximately the same (slightly lower) level of susceptibility as 
T246M towards limited proteolysis. The high amount of trimeric/tetrameric structures identified 
for this protein during gel-filtration analysis could indicate that the high proteolytic susceptibility 
of E28K is due to the unfolded/flexible structures of the protein molecule that appear during the 
formation of lower-order oligomers. 
 
5.2.4 Circular dichroism revealed new insights into the conformational dynamics and 
thermal stability of CHIP protein mutants 
The thermodynamic stability of protein folding, i.e. the Gibbs free energy difference between 
folded and unfolded states (∆G),  is generally determined by thermal unfolding spectroscopy 
whereby a protein solution is heated at a constant rate, and changes in its conformation are 
reported as melting temperatures (Tm) of the unfolding response [95, 96]. Denaturation of small 
globular proteins generally follows a two-state mechanism involving a single unfolding transition 
(Tm), and two forms of fully native (N) and unfolded (U) proteins [97, 98]. However, many 
proteins have been recently observed to stabilize intermediates between the N and U states, and 





usually found in multi-domain/multimeric proteins where different domains/meres unfold 
independently and at different temperatures. Analysis of data obtained from such curves is often 
more complicated than that of a single-stage unfolding pattern [95]. 
In the case of MBP-CHIP, the three transitions detected during thermal denaturation of the WT 
protein are assumed to be associated with unfolding of (in order) dimeric CHIP, MBP, and 
monomeric CHIP (Figure 4.10.1). As a dimeric protein, CHIP structure is stabilized by the 
intermolecular forces which hold proteins together as a dimer as well as intramolecular forces 
that occur within the monomers [100]. Therefore, it is possible that the disruption of 
intermolecular interactions during the first transition temperature (~44 °C) of MBP-CHIP 
proteins generates both dissociated MBPs and monomeric CHIPs in the protein solution being 
examined. After that, increased temperatures result in unfolding of each MBP and CHIP through 
disruption of interactions within the proteins (intramolecular interactions). Following the 
examination of MBP (only) for thermal denaturation (Figure 4.10.2), and based on other CD 
studies done on the unfolding transition of this protein [71, 101], the second transition on the 
unfolding curve of MBP-CHIP (~56 °C) is thought to belong to the melting of MBP. Therefore, 
CHIP itself (monomer) is expected to unfold at ~64 °C corresponding to the last transition 
temperature. 
The majority of mutants presented unfolding pathways with a similar level of cooperativity as the 
WT, indicating that the whole conformation and dynamics of the protein was not largely affected 
by the mutations. Differences, instead, appear to lie between the dimeric and monomeric 
unfolding transition temperatures determining the thermal stability of mutant protein structures. 
In the dimeric state, N65S was identified with a similar stability as the WT but higher than other 
mutants (Tm of 44.5 °C). The discovery of more dimers during gel-filtration analysis of this 
mutant can possibly explain this observation. Moreover, N65S was presented as the only mutant 
with an increased level of α-helicity and stability against limited proteolysis. Taken together, 
these findings indicate a stabilizing effect for N65S mutation, resulting in a more condensed 
CHIP protein structure.  
However, as a monomer, the highest thermal stability was displayed by S236T (Tm of ~74 °C). 





UV spectrum of the protein. Interestingly, at the same time, this mutant was associated with the 
least stabilized dimeric structure (Tm of ~41 °C). Therefore, a dual effect was observed for the 
S236T mutation, resulting in two completely different levels of stability for dimeric and 
monomeric forms of the protein. This might indicate that S236T does not form stable dimers and 
can be functional as a monomer, although such a hypothesis is not supported by gel-filtration 
analysis results where S236T displayed a dimeric peak similar to the WT. Further investigations 
are required in order to elucidate these findings precisely. 
Denaturation of the T246M mutants was characterized by less cooperative melting transitions, 
which may point to a loose, flexible tertiary structure. Results from limited proteolysis support 
this idea, indicating a high level of flexibility in the structure of this mutant as a result of initial 
formation of aggregations. The large loss of secondary structure content observed during the far-
UV spectroscopy of T246M can also explain the flexibility of its protein structure. In addition, 
the first transition corresponding to denaturation of dimeric intermediates was not found in the 
unfolding pathway of T256M. This observation correlates nicely with the gel-filtration analysis 
results where no peak associated with dimers was detected on the chromatogram of the T246M 
variant. In summary, the T246M mutation is likely to cause a high tendency for oligomerization 
in the CHIP protein structure which can be responsible for the lack of activity in corresponding 
mutants. However, on the way to the formation of aggregates, CHIP achieves a loose and flexible 
structure characterized by reduced stability toward proteolysis and a non-cooperative thermal 
unfolding profile.  
 
5.3 Expression levels of exogenous CHIP under the effect of mutations 
A pilot experiment was performed to study the effect of STUB 1 mutations on the expression 
levels of exogenous CHIP in HEK293 cells. The results from this initial analysis indicated an 
increased level of expression of E28K, N65S, K145Q, and M211I mutants (Figure 4.12.1). These 
observations do not follow the in vitro analysis of CHIP mutants, where a stabilized protein 
structure was detected only for N65S, and other mutations were associated with reduced 
structural resistance and secondary structure content. Furthermore, the immunoblot analysis of 
fibroblasts showed decreased levels of steady-state CHIP in patients carrying E28K, N65S and 





were detected compared to the WT in this study. In vitro analysis of T246M showed a high level 
of structural flexibility and aggregation for this mutant, while S236M mutation caused slighter 
changes in the structure of CHIP compared to T246M. No studies are available yet reporting the 
expression of these mutants in fibroblasts from patients.  
These findings must be considered preliminary before they have been supported by further 
experiments. In fact, due to the lack of transcription control (which verifies that the same levels 
of RNA are produced for all the mutants), false results can be achieved as a result of differences 
in transfection efficiencies. Furthermore, more repetitions of the experiment are necessary to 
obtain statistically valid data, which unfortunately was not possible within the limited time-frame 
of this project. 
 
5.4 Conclusion 
This study through examining the activity and structural properties of the encoded CHIP protein 
mutants provided further evidence regarding the role of STUB 1 mutations in the development of 
ARCA disease. The main results are summarized in Table 5.4.1. The ubiquitination activity of 
CHIP was impaired under the effect of mutations N65S and T246M while other mutants showed 
intact activities. Increased amounts of dimers as well as higher levels of secondary structures 
were discovered for CHIP-N65S, possibly resulting in the higher stability observed against 
limited proteoly°°sis and thermal unfolding. In contrast, T246M mutation generated a flexible 
protein structure with decreased α-helicity and a high tendency for aggregation. The CHIP-
T246M mutant presented the lowest stability against limited proteolysis. No dimeric unfolding 
transition was detected during their thermal denaturation. However, as a monomer, thermal 
stability of these mutants was found to be greater than the WT. Other mutations including 
K145Q, M211I, and S236T modified CHIP structure and conformation to a similar degree. 
Decreased secondary structure content and proteolytic stability was observed for these variants. 
Changes were detected to a lesser extent than those caused by T246M mutation. In addition, 
proteins became less resistant in terms of thermal unfolding while existing as dimers. However, 
different results were obtained regarding the stability of monomers against thermal denaturation. 
Finally, the expression levels of exogenous CHIP were increased in HEK293 cells for all the 
mutants excluding S236T and T246M among which, S236T was associated with the lowest 





Table 5.4.1 Summary of data achieved during this master project. Results for ubiquitination 
activity, structural/conformational characterizations, and exogenous expression levels of CHIP protein 
mutants are presented together with the WT. For each mutant, upwards and downwards pointing arrows 
indicate increased and decreased levels when compared to the WT, respectively. No dimeric unfolding 
was detected in the case of T246M. 
 
5.5 Future perspectives 
Future studies should focus on the in cellulo characterization of STUB1 mutations using more 
relevant cell lines such as neuronal cell lines or induced Pluripotent Stem cells (iPSCs). Using 
this approach, major findings achieved during this study including high aggregation propensity of 
T246M and structural stability of N65S can be analyzed through different fluorescence 
techniques inside the cells. Moreover, study of interactions between CHIP and other co- As 
mentioned earlier, there are currently 18 STUB1 mutations identified by exome sequencing in the 
genome of patients with ARCA disease. The number of these mutations is increasing rapidly, 
making the experimental measurement of the functional impact of each variant require much 





mutations, which will provide a high-throughput prospective interpretation of all variants within a 
short time, will be of great future interest. The potential of this new approach has been recently 
demonstrated in a study where nearly 2000 variants of the breast cancer-associated gene BRCA1 
were characterized using this technique [102]. 
Finally, given the fact that protein aggregation is the most common phenotype of many complex 
diseases, results obtained from ARCA cases can be successfully used in the study of Alzheimer, 
Parkinson and many other protein aggregation diseases as well. For instance, recent studies 
indicated that CHIP cross-functions with Parkin E3 ligase as the main cause of hereditary 
Parkinson disease [103]. Thus, functional analysis of Parkin in association with STUB1 mutations 
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7.1 Far-UV spectra of WT and mutant CHIPs in the wavelength range of 190-
260 nm 
Due to the buffer noise at wavelengths lower than 200 nm, results for the far-UV spectra were 
given in the range of 200-260 nm (Section 4.9). The original data is shown here:  
 
             





7.2  MicroScale Thermophoresis (MST) analysis 
The binding of Hsp70 to CHIP was quantified through measuring the changes in thermophoresis 
(directed movement of molecules along a temperature gradient) of Hsp70 as a fluorescent 
molecule at different ligand (CHIP) concentrations. Since the buffer is kept constant, alterations 
in the thermophoretic depletion or enrichment can only arise from changes in size, charge, or 
solvation entropy of the fluorescent molecule, indicating the presence of interaction between the 
molecule and ligand. Therefore, different traces can be observed as the thermophoretic movement 
of fluorescent Hsp70 changes upon binding to the non-fluorescent CHIP. For analysis, the change 
in thermophoresis was expressed as the change in normalized fluorescent (∆Fnorm), which is 
defined as Fhot/Fcold (average fluorescent values between hot and cold areas), and further plotted 
against different concentrations of ligand. 
        
Figure 7.2.1 MST experiment of NT-647-Hsp70 VS. CHIP. A fluorescent label (NT-647) was 
covalently attached to the Hsp70 protein. The concentration of NT-647 labeled Hsp70 was kept constant 
while the concentration of CHIP is varied between 0.3 nM to 10 µM. The assay was performed in MST 
buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl2, and 0.05% Tween. After a 
short incubation, the samples were loaded into MST NT.115 standard glass capillaries and the analysis 
was performed using the Monolith NT.115 instrument. Concentrations on the X-axis are plotted in nM. 
A Kd of 73 nM and 9 nM was determined for the WT CHIP and CHIP-E28K, respectively. No binding 
was observed between Hsp70 and CHIP-N65S mutant. 
 
